AUTHOR INDEX

Abel L, 1333
Abeloff MD, 1041
Abraham S, 267
Abrams J, 1626
Achanzar WE, 1888
Acorda E, 670
Adams J, 835
Addo FK, 855
Adjei AA, 1031
Agrawal D, 513
Agus D, 1641
Ahuja N, 755
Ainsworth P, 1773
Akerley WL, 284
Alberts DS, 1620
Albertsen PC, 430
Alexander BH, 943
Alitalo K, 819
Allison CJ, 1445
Allred DC, 662, 1722
Alvarez RD, 741
Ambrosone CB, 1635
Amos CI, 681, 1091
Andersen MR, 1346
Anderson MA, 422
Anderson KE, 1168
Anderson RL, 4
Anderson S, 852
Anderson WF, 1126, 1507
Andersson M, 182
Andreoni B, 1763
Anichini A, 805
Apple RJ, 866, 1780
Ardekani A, 1576
Arts E, 718
Ashley R, 1604
Askling J, 6768
Assimakopoulou M, 267
Aste H, 1763
Atkin WS, 1763
Auersperg N, 1255
Austin MA, 1185
Autier P, 772
Auvinen A, 1330
Avorn J, 652, 1652

Baba M, 1569
Baccarelli A, 94, 772
Baccarini S, 1854
Bach PB, 861, 1584
Baildam A, 307
Bailey J, 1484
Baker SD, 1883
Balis FM, 78
Ballard-Barbash R, 1151, 1546, 1837
Banura C, 718
Bao R, 522
Barata F, 1211
Barcellos-Hoff MH, 1494, 1894
Barlow WE, 1151, 1546
Barnes MN, 741
Barton MB, 1371
Bauer JA, 1010
Baylin SB, 26
Beach D, 446, 866
Becroft DMO, 1809
Beesley C, 482
Beex LVAM, 116
Begg CB, 861, 1044, 1221
Bégin LR, 1504
Beli TR, 463
Belin TR, 39
Bendahl P-O, 116
Bendix R, 205, 952
Benk V, 1143
Bennett DC, 446, 866
Benowitz NL, 108
Benson III AB, 1160
Benson JR, 1336
Bentley RC, 50
Berbaum K, 369
Berchuck A, 50
Bereiter-Hahn J, 1863
Bergman W, 894
Bernardo P, 173
Berstein LM, 1173
Bertucci F, 1506
Bhagat S, 17
Bhargava V, 1688
Bhatia K, 1757
Biggar RJ, 1204
Biocca S, 1031
Birnbaum D, 1506
Bishop DT, 894
Bishop JN, 894
Bissell MJ, 4, 1494, 1894
Black WC, 167, 861, 1066
Blackstock AW, 284
Blankenstein MA, 116
Blaser MJ, 1662
Blumenthal PD, 1469
Boer R, 193, 981
Boice Jr. JD, 182, 943
Bonadona V, 1582
Bonelli L, 1763
Bonham MJ, 1641
Boniol M, 772
Bonomi P, 173
Boone K, 592
Borner MM, 1653
Borstnar S, 116
Bosch FX, 1604
Bosetti C, 1604
Bosken CH, 1091
Botti C, 1719
Botto B, 26
Bowman R, 949
Boyd J, 990
Bracci PM, 297
Bradley CJ, 490, 1254
Brain A, 307
Brambila EM, 1888
Brantley KR, 990
Bratti MC, 866
Brawley OW, 471
Breast Cancer Linkage Consortium, 1358
Brèdart A, 1810
Breen N, 1837
Bresalier R, 1854
Bressac-de Paillerets B, 894
Brinkley W, 1320
Brinton LA, 1780
Brockmöller J, 630
Broët P, 116
Broman KW, 1809
Bromley C, 866
Bromley RL, 866
Brose MS, 1365
Broughton L, 1484
Brown A, 852
Brown EE, 1712
Brown ML, 334
Brugarolas A, 1175
Brunet J-S, 1504, 1773
Brünner N, 116
Bryant J, 852
Buetow K, 866
Bugajska U, 1381
Buller RE, 61, 1396
Bullock N, 1071
Burk RD, 866
Burke W, 1185
Burstein HJ, 866
Busam K, 1803
Buttar NS, 422

Caldas C, 1680
Calingaert B, 32
Calvo E, 1175
Calzone KA, 1365
Canevari S, 1031
Canil CM, 1422
Cantor A, 513
Capelinha AF, 1680
Capello D, 26
Carbone A, 26
Carbone M, 229
Carlini P, 1719
Carneiro F, 1680
Carnevale KA, 1010
Carney PA, 321, 1151, 1546
Carvalho R, 1680
Castelli C, 805
Castellon SA, 547
Castellsagué X, 1604
Castle PE, 1406
Catalano PJ, 769, 1160
Cayrou S, 1810
Cella D, 173
Chambers AF, 513
Chan ATC, 1614
Chan DW, 1697
Chan JM, 1099, 1893
Chan KYK, 1581
Chan LYS, 1614
Chan MYM, 1249
Chan PKS, 1249
Chang H-W, 1697
Chang L, 592, 1336
Chang S, 369
Chapman RS, 826
Chappuis PO, 1504
Chasan R, 3
Chaudhuri TR, 741
Che M, 17
Chen B, 1458
Chen C-J, 1780
Chen C-S, 585, 1745
Chen GA, 504
Chen I-H, 1780
Chen J, 1653
Chen JX, 1527
Chen T, 513
Chen X, 205, 952
Chen Z, 1226
Chen, FL 1445
Chenevix-Trench G, 205, 951, 952
Cheng AF, 1249
Cheng Y-J, 1780
Cheong SC, 446, 866
Cher ML, 17
Cheung ANY, 1581
Cheung JLK, 1249
Cheung T-H, 1249
Chew K, 1688
Chin JL, 1458
Chin L, 446, 866
Chittenden A, 844
Chlebowski R, 592, 1336
Cho SKR, 1697
Chokkalingam AP, 1648
Chompret A, 894
Christen M-O, 1001
Christensen IJ, 116
Christiansen CL, 1373
Church TR, 861
Clarke B, 949
Clarke EA, 182
Classical Kaposi's Sarcoma Working Group, 1712
Claustrat B, 690
Cleary MP, 1704
Clegg LX, 430, 1537
Cler L, 858
Cline M, 50
Cognetti F, 1719
Colditz GA, 437, 530, 1393, 1301
Coldman A, 1001
Coleman CN, 1594
Coleman R, 926
Colowick AB, 1211
Concetti A, 1808
Connolly DC, 522
Cooray D, 592
Copenhafer DL, 1877
Coppola D, 513
Cordon-Cardo C, 1803
Coriaty Z, 1445
Correia N, 497
Costantino JP, 1504
Couch F, 1773
Cowley H, 369
Cox JT, 102
Crawford B, 844
Cronin WM, 1504
Cronk M, 88
Crosta C, 1763
Croul S, 267
Crowley JJ, 291
Cufer T, 116
Cummings M, 205, 952
Cummings S, 844
Curiel DT, 741
Curtis RE, 1330
Curtis RE, 182
Cutter GR, 1151, 1546
Cuttitta F, 1226
Czerniak B, 1320
Dabney S, 1010
D'Agostino RB, 1877
Dahiya R, 384
Dale JK, 1757
Dalerba P, 805
Daly M, 1773
Dannenberg A, 545
Dardes RC, 274, 1173
Daver A, 116
Davidson NE, 855
Davis S, 530, 1578
Daxenbichler G, 116
de Bruijn P, 1247
de Chive-Lowe P, 1071
de Lemos M, 1652
De Los Reyes A, 267
De Stavola BL, 1238
Dearnaley D, 861
Del Valle L, 267
Delbue S, 267
Demenais F, 894
DeMets DL, 662, 1722
Deng J, 1648
DePinho RA, 446, 866
Desmond KA, 39, 463
Desmond RA, 741
Detjen K, 129
Devarajan E, 1653
Devesa SS, 1204

DeVries S, 1688
DeYoung B, 1396
Dharia A, 384
Di Cosimo S, 1719
di Tommaso D, 981
Diamond EJ, 1893
Dickman PW, 497
Dierkhising RA, 422
Dilworth SM, 1071
Dinh NV, 662
Diwan BA, 1888
Djoussé L, 1877
Doble A, 1071
Dodge RK, 50
Dolan ME, 6
Dolbeault S, 1810
Dolezal M, 1275
Donehower RC, 1883
Donlon T, 454
Donn K, 205, 952
Doody MM, 943
Doré J-F, 772
Dorgan JF, 1877
Dörk T, 205, 951, 952
Dowlati A, 718
Drazba J, 1010
Drenning SD, 633
Drobnjak M, 1803
Droller MJ, 1893
Druker BJ, 1660
Dubé M-P, 1773
DuBois RN, 406, 545, 1732
Duc NB, 662
Duell EJ, 297
Duffy MJ, 116
Duggan C, 116
Duhig E, 949
Dunger DB, 972
Dunstan HM, 88
Dyachkova Y, 1001
Dyer KF, 375

Easton DF, 1358
Easty DJ, 446, 866
Eberle C, 369
Ederer F, 861
Eisinger F, 461, 1506
El-Ghany MA, 482
El-Guindy A, 1733
Ellison RC, 1877
Elmore JG, 321, 1373
Eltom MA, 1204
Eluf-Neto J, 1604
Emi N, 1807
Emmert-Buck MR, 1576
Enam S, 267
Eng C, 1688
Eppenberger U, 116
Eppenberger-Castori S, 116
Erlich HA, 1780
Ernst T, 592, 1336
Ernster VL, 1546
Esserman L, 369, 844, 1582
Esteller M, 26
Etzioni R, 981, 1346
Euhus DM, 844, 858, 1582
Evans DG, 307
Evans DRH, 88
Evans G, 1773
Evans I, 1445
Evans-Whipp TJ, 446, 866

Fabi A, 1719
Fabian CJ, 844
Farr G, 926
Fay MP, 1537
Feinberg AP, 1809
Felicetti P, 1808
Feng Z, 1527
Fenton BT, 417
Fernández-La Torre F, 1175
Fernö M, 116
Ferraresi V, 1719
Ferraris R, 1763
Ferreccio C, 1688
Ferretti G, 1719
Feuer EJ, 904, 981, 1537, 1626
Fidler IJ, 1134
Fiegl M, 1211
Fiets WE, 116
Figini M, 1031
Figueiredo C, 1680
Filipski E, 690
Fine HA, 240
Fleishman S, 284
Fletcher SW, 1373
Floderus B, 1238
Foekens JA, 116
Folkman J, 883
Folsom AR, 1168
Fong K, 949
Font A, 1211
Foster CS, 482
Foulkes WD, 1504, 1773
Franceschi S, 1604
Fraumeni Jr. JF, 182, 1648
Freedman DM, 943
Fridman R, 17
Friedman E, 1773
Fuchs CS, 437, 1160, 1293
Fujii H, 1555
Fujimoto S, 384
Fukusato T, 1080
Fyles A, 1143

Gafà L, 1712
Gaffikin L, 1469
Gaidano G, 26
Gail MH, 861
Gajdos C, 274
Gale A, 369
Galkin A, 1641
Gallo C, 1029
Gamero AM, 1010
Gandara DR, 291
Gann PH, 981, 1099
Ganz PA, 39, 463, 547, 835, 844, 1582
Gao DL, 1445
Gao Y-T, 749, 1648
Garayoa M, 1226
Garber JE, 844, 1773
Gasperoni S, 1763
Gatei M, 205, 952
Gateley J, 1211
Gauthier-Villars M, 1773
Gazdar AF, 858, 1001
Gaziano JM, 1099
Geisler JP, 61, 1396
Geller BM, 1151, 1546
Geng L, 733
Gentry J, 530
Georgopoulos NT, 1381
Gershoni-Baruch R, 1773
Gessain A, 1333
Ghadirian P, 1773
Ghannoum M, 718
Ghiorzo P, 894
Giannarelli D, 1719
Giantonio B, 769
Gilbert E, 182
Gill J, 926
Gilliland FD, 430
Giovannucci E, 391, 437, 972, 1099, 1293
Giuliano AR, 1620
Gius D, 1594
Given CW, 490
Glass AG, 1406
Gleason DM, 1458
Glimelius B, 182
Glimelius I, 182
Gloghini A, 26
Glustrom LW, 1337
Goas JA, 1458
Goedert JJ, 1712
Goehle S, 88
Goffin J, 1504
Goldammer M, 630
Goldstein AM, 894
Gooding WE, 375
Goodman SN, 26, 1697
Gordon J, 267
Gordon J, 1381
Gospodarowicz M, 182
Graber P, 1381
Granda TG, 690
Grandis JR, 375, 633
Grane RW, 1010
Granström C, 1892
Graziano SL, 284
Green J, 522
Green MR, 284
Greiner TC, 1757
Grevstad P, 291
Gridelli C, 1029
Gridley G, 1648
Grimard L, 1143
Grochow LB, 1883
Groenewegen G, 1484
Groshen S, 936
Grossman HB, 1320
Grossman L, 94, 772
Gruber J, 1832
Gruber SB, 1344
Gruis N, 894
Gubish C, 375
Guédez L, 1226
Guilland M, 1001
Guillén-Rodríguez JM, 1620
Gulavita S, 1143
Guo ZS, 504
Gupta RA, 406
Gutiérrez MI, 1757
Guyton KZ, 1126, 1507

Habbema JDF, 193
Haberl M, 630
Habib NA, 755
Hackett PS, 1576
Haggstrom DA, 167, 861
Hahnfeldt P, 883
Hail Jr. N, 1281
Hajduch M, 1275
Hakannson L, 1484
Hales CN, 1071
Hall WA, 597
Hallahan DE, 733
Haller DG, 1160
Halpern E, 861
Halsall I, 1071
Hamajima N, 1807
Hamilton TC, 522
Hankey BF, 904, 916, 1537
Hankinson SE, 1301
Hansen J, 530
Hansen RK, 1494, 1894
Hansson J, 894
Harbeck N, 116
Harlan LC, 1626
Harland M, 894
Haroon H, 1484
Harris R, 1420
Hartmann L, 143, 307
Hastings D, 1484
Hastings MH, 690
Hatake, K 1020
Hatterman-Zogg MA, 61, 1396
Hauptmann M, 943
Havighurst TC, 662
Hawes SE, 1592
Hawk ET, 545, 1001, 1126, 1507
Hayasawa H, 1020
Hayward N, 894
Hazan C, 1803
He X, 826
He Y, 633, 819
Heda S, 858
Hedayati M, 94, 772
Hedenfalk IA, 960
Heimdal K, 1773
Hemminki A, 741
Hemminki K, 461, 1892
Henley SJ, 252
Herman JG, 26
Herndon II JE, 284
Herold M, 1484
Herrera B, 108
Herrero R, 866, 1604
Herzog M, 17
Hiatt RA, 1126, 1507, 1837
Hildesheim A, 866, 1780
Hill SP, 446, 866
Hiller W, 852
Hilton JL, 1396
Hirano T, 1790
Hirose K, 1807
Hishida A, 1807
Hislop TG, 670
Hitt BA, 1576
Hjalgrim H, 678
Hlatky L, 883
Ho S, 1614
Ho S-M, 617
Hoedemaeker RF, 227
Hoffman RM, 430
Hogan V, 1854
Holland EA, 894
Holland J, 284
Holly EA, 297
Holm NV, 1238
Holmes MD, 1301
Holowaty E, 182
Hong WK, 681
Honjo Y, 1854
Hood M, 1877
Hopper JL, 205, 951, 952
Hopwood P, 307
Hortobagyi GN, 641, 1722
Houghton A, 1803
Howell A, 307
Hrushesky WJM, 1719
Hsing AW, 1648
Hsu M-M, 1780
Hu W, 1527
Hu X, 1704
Hu YW, 1445
Huang DP, 1614
Huang L, 633
Huang S, 1134
Hughes CL, 50
Hughes KS, 844
Hung M-C, 1527
Hunter DJ, 1337
Hustert E, 630
Hutchins LF, 1635

Ibrahim MM, 1757
Ihse I, 632
Ijiri R, 358
Ikeda K, 1020

Ingle JN, 855
International Breast Cancer Study Group (IBCSG), 1054, 1338
Irby R, 513
Isaacs C, 1773
Ishizaka Y, 1020
Isner P, 50
Issa J-PJ, 755
Ito S, 1080, 1320
Iwata H, 1807

Jackson A, 1484
Jackson JC, 670
Jacob III P, 108
Jacobs BS, 1010
Jacobs ET, 1620
Jain RK, 417, 785
Jänicke F, 116
Jayson GC, 1484
Jazaeri AA, 990
Jemal A, 1204
Jenkins MA, 205, 952
Jenkins RB, 855
Jernstrom H, 1773
Jiang F, 1320
Jin N, 597
Jing C, 482
Joensuu T, 182
Joffe S, 1847
Johnson AJ, 585
Johnson DH, 173, 1029
Johnson JL, 718
Johnson KA, 1626
Johnson PJ, 1614
Johnson PWM, 1381
Johnson TW, 1168
Johnston D, 1320
Jordan VC, 274, 1173
Jovicich J, 592
Juffs HG, 156
Julian J, 1143
Julyan P, 1484
Juneja SC, 1704

Kaaks R, 454
Kachnic LA, 704
Kadlubar FF, 681, 1635
Kahn KL, 835
Kalman D, 1688
Kamino H, 1803
Kanda S, 1311
Kanetake H, 1311
Kaprio J, 1238
Karagas MR, 224
Karpanen T, 819
Kates R, 116
Katki HA, 861
Kato K, 358
Katongole-Mbidde E, 718
Katsetos CD, 267
Katsuyama M, 1020
Katz RL, 1320
Katz-Brull R, 1197
Kaufman PA, 855
Kaufmann M, 1863
Kaur G, 1226
Ke Y, 482
Kelley MJ, 774, 1516
Kelly H, 205, 952
Kelly K, 291
Kelsey KT, 297
Kerenyi N, 530
Kerlikowske K, 1151, 1546
Kessler LG, 1346
Khalili K, 267
Khanna KK, 205, 952
Khoo U-S, 1581
Kigasawa H, 358
Kim-Sing C, 1773
King J, 1469
King VM, 690
Kinsinger LS, 1420
Kirchheiner J, 630
Kirk J, 205, 952
Kirkpatrick A, 369
Kishida T, 1569
Kishikawa M, 1555
Kitanaka C, 358
Kiviat NB, 1592
Klabunde C, 1837
Klattig J, 630
Klein K, 630
Kleinman HK, 1226
Klemp J, 844
Klijn JGM, 116, 1773
Klitz W, 1780
Ko H-H, 1581
Kobayashi K, 1569
Kobuke T, 1555
Koch I, 630
Koepsell TD, 861
Kohn EC, 1113, 1576
Konas M, 1275
Kondo K, 1569
Kopans DB, 861
Kopf AW, 1803
Kops SP, 229
Koshikawa K, 819
Kosty MP, 284
Kotcherguina I, 384
Kozaki K, 819
Kramer BS, 3
Kreger BE, 1877
Kreuter W, 1373
Krishnadath KK, 422
Kubota S, 1080
Kubota Y, 1569
Kuchino Y, 358
Kueng W, 116
Kugler JW, 173
Kulp SK, 585
Kuniyuki A, 670
Kuriyama T, 772
Kurman RJ, 1697
Kwan L, 835
Kwate NOA, 1254

La Vecchia C, 529
Lacombe L, 1458
Lada B, 1143
Laden F, 1337
Lai M, 1614
Lai T-W, 1581
Lalloo F, 307
Lam C-W, 1249
Lam S, 1001
Lamb JR, 88
Lan Q, 826
Landi MT, 94, 772
Lang NP, 1635
Langer CJ, 173, 1029
Langley R, 1134
Lango MN, 375
Laouri M, 835
Larsen J, 949
Lasset C, 1582
Laukkanen E, 1143
Lauria C, 1712
Lavin PT, 1197
Lawrance J, 1484
Lawrence WF, 1469
Lazovich D, 1168
Le Beyec J, 4
Le Marchand L, 454
le Riche JC, 1001
Lederman MM, 718
Lee KL, 50
Lee SM, 1697
Leedham B, 39, 463
Legler JM, 981
Lehman CD, 1151
Lehmann FF, 1484
Lehrer S, 1893
Lei H, 951
Leitch AM, 858
Lenkinski RE, 1197
Lenoir GM, 1582
Lenz H-J, 936
Leung S-F, 1614
Levi F, 529
Lévi F, 690
Levin B, 1126, 1507, 1790
Levine M, 1143
Levine PH, 1780
Levine PJ, 1576
Levitt D, 1484
Li C, 597
Li H, 1527
Li S, 762
Li W, 1445
Li WWH, 1249
Li X, 690
Limpahayom KK, 1469
Lin H-P, 585, 1745
Lin MG, 1445
Lin Q-Q, 866
Lindblom A, 951
Linehan WM, 1576
Linet MS, 943
Liotta LA, 1113, 1576
Lippman SM, 529
Lisboa BW, 116
Littman SJ, 1516
Liu B, 741
Liu ET, 990
Liu H, 1173
Liu M, 297
Liu S, 1293
Liu X, 690
Liu Y, 391
Lo KWK, 1249
Lo YMD, 1614
London SJ, 749
Look MP, 116
Loos WJ, 1247
Lorincz AT, 1406
Lotan R, 469, 1281
Lovato LC, 291
Love RR, 662, 1433, 1719, 1722
Lubin JH, 943
Lubinski J, 1773
Ludlow C, 88
Lui VWY, 375
Lukka H, 1143
Lumbiganon P, 1469
Lutzke LS, 422
Lu-Yao G, 958
Lynch CF, 182
Lynch HT, 461, 1773

Ma BBY, 1614
Ma J, 1099
Mabuchi K, 1555
MacAulay C, 1001
Macdonald JS, 1160
Machado JC, 1680
Machala M, 1275
Mack SJ, 1780
Mack T, 1238
Mackall CL, 1673
MacKenzie R, 1143
Madigan MP, 1648
Madsen M, 678
Magdelenat H, 116
Magnusson CM, 497
Maihle NJ, 1704
Makan N, 681
Malayeri R, 1172
Malin JL, 835
Malone T, 769
Mandel JS, 861
Mandelblatt JS, 1469
Manders P, 116
Mann GJ, 205, 894, 952
Manola J, 173
Mansky PJ, 1187
Mantelli M, 894
Mao L, 949
Marchand A, 670
Marchbanks PA, 32
Marcu MG, 504
Marincola FM, 805
Mariotto A, 1626
Marquez VE, 1745
Marr J, 1071
Marreaud S, 1484
Marsh A, 205, 952
Martin P-M, 116
Martínez A, 1226
Martínez ME, 1620
Martino S, 855
Massuti B, 1211
Matanoski GM, 943
Mathijssen RHJ, 1247
Matsumoto-Mishima Y, 1020
Matsuo K, 1807
Mayer RJ, 1160
Mbulaiteye SM, 1204
McCarty M, 1134
McCollum AD, 1160
McCredie MRE, 205, 952
McGown AT, 1484
Mehta K, 1653
Meijer CJLM, 1604
Meijer-van Gelder ME, 116
Melbye M, 678
Melhem MF, 633
Melzer K, 1803
Mennecozzi M, 1808
Merajver S, 1773
Merchant MS, 1673
Meruelo D, 1790
Messina A, 1712
Metcalfe KA, 1564
Meyerowitz BE, 39, 463
Michaud DS, 1293
Midthune DN, 1537
Miglioretti DL, 1373
Milchgrub S, 858
Milella M, 1719
Miller AA, 1822
Miller AB, 308
Miller BA, 904, 916
Miller FG, 1821
Miller Jr. IG, 1733
Mills GB, 844, 1582
Mirick DK, 530, 1578
Mishima Y, 1020
Mitton-Fry RM, 1337
Miura T, 1569
Miyata Y, 1311
Mizunuma N, 1020
Mo F, 1614
Mochizuki Y, 1311
Mohan AK, 943
Moinpour CM, 291
Mok SC, 617
Moller P, 1773
Momoi T, 358
Montella M, 1712

Montgomery B, 1641
Montz FJ, 1697
Monzo M, 774
Moody T, 1226
Moon C, 949
Moore II D, 1688
Moore LE, 1688
Moorman PG, 32
Mori M, 1020
Morison IM, 1809
Moriyama M, 1569
Mormont M-C, 690
Morrison BH, 1010
Mortarini R, 805
Mott LA, 224
Mottolese M, 1719
Mulatero C, 1484
Mullins C, 17
Multani A, 1653
Muñoz N, 1604
Murphy B, 855
Murphy M, 522
Murray R, 1458
Muscato JJ, 284
Musil J, 1211

Nagao K, 772
Nagarsheth NP, 50
Nagashima Y, 358, 1569
Nagourney R, 1275
Nakagawara A, 358
Nakaigawa N, 1569
Nakatani Y, 1569
Nancarrow D, 894
Nangia-Makker P, 1854
Narod SA, 1564, 1773
Nathanson KL, 1365
Neckers L, 504
Nelson PS, 1641
Nelson W, 143, 307
Nemeth JA, 17
Nemoto T, 1080
Nersesyan AK, 949
Neuhausen SL, 1773
Newell SA, 558, 1810
Nguyen DM, 504
Nilsson H-O, 632
Nilsson S, 497
Nishi T, 358
Nisticò C, 1719
Noguchi K, 358
Noguchi T, 461
Nordlinder H, 497
Nowell S, 1635
Nyholt D, 205, 952

O'Dwyer PJ, 769
O'Higgins N, 116
O'Regan RM, 274
Oefner PJ, 774
Offit K, 1773
Olopade OI, 844, 1773
Olsson H, 1773
Orlow SJ, 446, 866
Ornstein DK, 1576
Ørntoft TF, 216
Osborne M, 1773
Osman I, 1803
Otieno MW, 718

Pacifico RJ, 422
Padera TP, 783
Pagano JS, 1832
Paik S, 852
Pampeno C, 1790
Pan LD, 1445
Panageas KS, 1803
Panoskaltsis-Mortari A, 597
Pao A, 1527
Papaldo P, 1719
Park DJ, 936
Park W, 274
Park K, 852
Parker C, 861
Parmiani G, 805
Partridge AH, 652, 866, 1652
Pasini B, 1773
Paskett ED, 284
Pass HI, 229
Pathak S, 1653
Patrono C, 252
Paweletz CP, 1576
Pedeux R, 772
Peng X, 926
Penna A, 1763
Penson DF, 981
Perera F, 1143
Perez EA, 855
Pérez-Stable EJ, 108
Perinchery G, 384
Perlman EJ, 1809
Perneger TV, 308
Perrone F, 1029
Perry MC, 284
Persson IR, 497
Pesatori AC, 94, 772
Peters GN, 858
Peters M, 129
Petersen GM, 872, 1344
Petersen OW, 1494, 1894
Petricoin III EF, 1576
Peyrat J-P, 116
Pharoah P, 1680
Philip N, 461
Philips J, 1433
Pickle LW, 904
Pio R, 1226
Pirker R, 1211
Pirnia F, 1653
Pirruccello S, 461
Pisarcik DA, 522
Plancoulaine S, 1333
Plath T, 129
Platz A, 894
Pollak M, 1099
Polsky D, 1803
Porock D, 530
Porter P, 1445
Pospisilova D, 951
Potosky AL, 430
Powell SN, 704
Prakash O, 926
Presant CA, 291
Preston DL, 1555
Prevost AT, 1071
Primdahl H, 216
Provencher D, 1773
Pukkala E, 182
Pupo GM, 205, 952

Quackenbush J, 513
Quillien V, 116
Quinn-Laquer B, 461
Quint W, 1680

Raab-Traub N, 1832
Rabkin CS, 678
Rademaker AW, 274
Radhakrishnan S, 267
Radisky D, 1494, 1894
Radke C, 129
Ramsey SD, 291, 1172
Randimbison L, 529
Ranson M, 1484
Rashid A, 755
Rathe JA, 61, 1396
Ravenel JD, 1809
Ray RM, 1445
Raz A, 1854
Rebbeck TR, 630, 1365
Reeve AE, 1809
Reeve BB, 430
Reisch LM, 1373
Remick SC, 718
Renne R, 718
Rennert G, 1773
Rey OA, 1688
Reynolds CP, 319
Rezza G, 1712
Ricolleau G, 116
Rieger P, 844
Riman T, 497
Rimm EB, 391
Rinaldi S, 454
Ringers P, 1469
Risch HA, 308
Risio M, 1763
Rivkin SE, 291
Rivoltini L, 805
Roberts C, 490
Robinson L, 844
Robson M, 1773
Roche CA, 844
Roche PC, 855
Roden R, 1697
Rodriguez GC, 32
Rodriquez AC, 866
Rodriquez GC, 50
Roe DJ, 1620
Rogers BE, 741
Rom W, 1527
Romain S, 116
Romano N, 1712
Romond E, 852
Ron E, 943, 1330, 1555
Rosell R, 774
Rosenberg R, 1151, 1546
Rosewicz S, 129
Ross RK, 749
Rossi D, 26
Rossini FP, 1763
Rostgaard K, 678
Rowinsky EK, 1883
Rowland JH, 39, 463
Rudland PS, 482
Ruifrok AC, 1320
Rush BB, 1406
Russell W, 706

Saad F, 1458
Saal HM, 1773
Sakurada K, 358
Šale S, 774
Salvador C, 592
Samaniego F, 926
Sambrook J, 205, 952
Sandhu MS, 972
Sanger WC, 461
Sanson-Fisher RW, 558, 1810
Santen RJ, 1173
Sartor CI, 1114
Sasaki M, 384
Sauvan R, 461
Savolainen NJ, 558, 1810
Scarpidis U, 866
Schatzkin A, 1877
Schellens JHM, 1883
Schernhammer E, 530
Schiffman M, 102, 866, 1406
Schildkraut JM, 32
Schiller JT, 1832
Schilsky RL, 6
Schmitt M, 116
Schrag D, 1044, 1584
Schreinemachers DM, 826
Schröder FH, 227
Schrump DS, 504
Schussler JE, 1406
Schwartz LM, 799, 1584
Schwartz SM, 670
Sciallero S, 1763
SCORE Working Group–Italy, 1763
Scott C, 205, 951, 952
Scott DR, 1406
Seetharam B, 1010
Lindner DJ, 1010
Segnan N, 1763
Seifried A, 454
Sekihara H, 1080
Selby PJ, 1381
Seldon J, 844
Self SG, 1445
Seligson AL, 1275
Sen S, 1320
Senore C, 1763
Sephton S, 530
Serraino D, 1712
Seruca R, 1680
Seyama Y, 1080
Shavers VL, 334
Shekarriz B, 17
Shelley W, 1143
Shen L, 755
Shen T-Z, 662
Shen Y, 755
Sherman ME, 102, 866, 1406
Shete S, 681
Shields PG, 1435
Shih I-M, 1697
Shin M-H, 1301
Shirouzu M, 358
Shivapurkar N, 858
Shureiqi I, 529
Shyr Y, 733
Siegfried JM, 375
Siena S, 1211
Sikic BI, 774
Silverman DHS, 547
Simon JA, 88
Simone CB, 1576
Singer G, 1697
Singh GK, 904, 916
Sinilnikova OM, 1582
Slattery MJ, 224
Sloan JA, 1184
Smith AH, 1688
Smith DJ, 1010
Smith JS, 1604
Smith KC, 844
Smith N, 1484
Smith P, 482
Smith R, 852
Sobol H, 461, 1506
Sobrinho-Simões M, 1680
Sokoll LJ, 1697
Soliman AS, 529
Song RX-D, 1173
Song X, 585, 1745
Sonnenschein C, 1173
Soria J-C, 949
Sotiriou C, 990
Soto AM, 1173
Sousa S, 1680
Southgate J, 1381
Sovak M, 1275
Soverchia L, 1808
Spänkuch-Schmitt B, 1863
Sparreboom A, 1247, 1883
Spencer SK, 224
Spiegel D, 530
Spira JG, 1803

Spitz MR, 681, 1091
Sporn MB, 242
Spurdle AB, 205, 952
Spyratos F, 116
Stahl WL, 1641
Stalsberg H, 1445
Stamey TA, 227
Stampfer MJ, 391, 1099
Stanford JL, 430
Stannard VA, 224
Stefanek M, 143, 307
Steinberg SM, 1576
Stenram U, 632
Stephenson RA, 430
Stetler-Stevenson WG, 1226
Stevens R, 530
Stock RG, 1893
Stoeber K, 1071
Stoehlmacher J, 936
Stone A, 1635
Stone NN, 1893
Stopfer JE, 1365
Storm HH, 182, 678
Stovall M, 182
Straus SE, 1187, 1757
Strebhardt K, 1863
Stucky A, 844
Suman VJ, 855
Sun P, 1773
Surh Y-J, 1263
Sviderskaya EV, 446, 866
Swan J, 1837
Swanson GP, 143
Sweeney C, 1635
Sweep CGJF, 116
Swerdlow AJ, 1238
Swinn R, 1071
Syed V, 617
Szabo M, 513
Szankasi P, 88
Szechtman B, 1143

Tagett R, 1506
Tait L, 1854
Tajima K, 1807
Takahashi T, 819
Takiguchi Y, 772
Talcott JA, 407
Tamburini M, 1712
Tanaka Y, 358, 384
Tan-Chiu E, 852
Tang M, 1484
Tang M-s, 1527
Tang Z-Y, 926
Tannock IF, 156, 1422
Taplin SH, 1151, 1546
Tarón M, 774
Tarone RE, 94, 772
Taylor VM, 670
Tchekmedyian S, 1458
Te V-C, 529
Tedjarati S, 1134
Teh C, 670
Tepper JE, 1114
Terai M, 866
Terui Y, 1020
Tevethia SS, 1832
The Endogenous Hormones and Breast Cancer Collaborative Group, 606
The Melanoma Genetics Consortium, 894
Thiele CJ, 1673
Thomas DB, 1445, 1578
Thompson B, 670
Thompson D, 1358
Thomssen C, 116
Thun MJ, 252
Tian L, 826
Tokunaga M, 1555
Tokuoka S, 1555
Tomita D, 1211
Tomiyama A, 358
Tomlinson G, 844, 1582
Toyoda Y, 358
Toyota M, 755
Travis LB, 182
Travlos GS, 749
Trejdosiewicz LK, 1381
Trucco C, 1576
Tsao-Wei DD, 936
Tseng J-C, 1790
Tseng P-H, 585
Tu S-P, 670
Tucker K, 205, 952
Tucker MA, 94, 772, 894
Tung N, 1773
Turley EA, 1494, 1894
Turner WH, 1071
Tweardy DJ, 633

Ulinski G, 617
Ulm K, 116
Upadhyay J, 17
Urban N, 1546

Vachon CM, 872
Vakar-Lopez F, 1320
Vallera DA, 597
Van Arsdall M, 1134
van Ballegooijen M, 193
van Beveren M, 1333
van den Akker-van Marle ME, 193
Van den Brule AJC, 1604
van der Kwast TH, 227
van Doorn L-J, 1680
van Leeuwen FE, 182
van Oortmarssen GJ, 193
van Putten WLJ, 116
Vansteenkiste J, 1211
Varricchio CG, 1184
Velassco A, 1576
Venanzi FM, 1808
Venner P, 1458
Verkasalo PK, 1238
Vernon SW, 1126, 1507
Verweij J, 1247, 1883
Vey N, 461
Viner JL, 545
Vinholes JJ, 1458
Vitale F, 1712
Vitolo U, 26
Vogel VG, 1504
von der Maase H, 216
von Marschall Z, 129
Vorechovsky I, 951
Vos M, 1226

Waalkes MP, 1888
Wacholder S, 866, 1406
Wadström T, 632
Wagner T, 1773
Wagstaff J, 1484
Waldman FM, 1688
Walmer DK, 50
Walot I, 592
Wang F, 1494, 1894
Wang KK, 422
Wang PS, 652, 1652
Wang SS, 1780
Wang WW, 1445
Warakamin S, 1469
Ward T, 1484
Warner E, 1773
Watanabe J, 1020
Watanabe R, 772
Weaver DL, 1151, 1546
Webber MM, 1888
Weber B, 1773
Weber BL, 1365
Weeks JC, 1847
Wei Q, 1091
Weiderpass E, 497
Weinstein JK, 522
Weinstock MA, 224
Weisenburger DD, 461
Weiss NS, 861
Weitzel J, 1773
Welch HG, 167, 799, 861, 1066, 1584
Welzel M, 129
Whalen C, 718
Whelan T, 1143
Whitaker RS, 50
White J, 1261
Wickerham DL, 852, 1504
Wiedenmann B, 129
Wiegand L, 1576
Wiencke JK, 297
Wikman FP, 216
Wilkens LR, 454
Willett WC, 391, 437, 1293, 1301
Williams GH, 1071
Wilson RE, 749
Windbichler G, 116
Winer EP, 652, 866, 1652
Winters M, 1635
Wojnowski L, 630
Wolf H, 216
Wolff AC, 1041
Wolff MS, 1337
Wolmark N, 852
Woloshin S, 799, 1584
Wong M, 1832
Wong N, 1504
Woo C-W, 1673
Wood K, 1576
Wu C, 1445
Wu K, 437, 1301
Wu W, 1134
Wu X, 681
Wun L-M, 1626
Wuttke DS, 1337

Xia X, 762

Yamada M, 1020
Yamamoto N, 1311
Yan S, 1745
Yang C-S, 1780
Yang Y-T, 585
Yankaskas BC, 1151, 1546
Yao M, 1569
Yao S-L, 958
Yasui Y, 670
Yeatman TJ, 513
Yee CJ, 990
Yee H, 1790
Yi B, 1469
Yip S-P, 1581
Yla-Herttuala S, 819
Yokoyama S, 358
Yoneda T, 1494, 1894
Yonehara S, 1555
Yoon DS, 1320
Yoshida M, 1569
Yothers G, 852
Young DC, 1745
Yousif R, 17
Yu MC, 749, 936
Yu X, 504
Yuan J-M, 749

Zagonel V, 26
Zang EA, 308
Zanger U, 630
Zappa M, 1763
Zee B, 1614
Zeng Q, 633
Zhang R-D, 1320
Zhang W, 936
Zhang X, 762
Zhang Y, 1877
Zhang Z, 1697
Zhao GL, 1445
Zhao H, 681
Zheng Y, 1151, 1546
Zheng Y, 1546
Zhou H, 1320
Zhou X, 216
Zhu J, 1745
Ziltener H, 1255
Zinn KR, 741
Zujewski J, 788
Zweit J, 1484
Zwierzina H, 1484

NEWS INDEX

Ablatherm
High-intensity focused ultrasound makes its debut, July 3, p. 962
Acrylamide
Acrylamide and cancer: Tunnel leak in Sweden prompted studies, June 19, p. 876
Advertising, *see* **Marketing**
Advocates
After Long Island study, advocates look for a stronger voice, Sept. 18, p. 1349
Age
Stat Bite: Cancer mortality rates age-adjusted by different age standards, 1973–1999, May 15, p. 711
Stat Bite: Frequency of cervical cancer screening by age group, 2000, June 19, p. 879
Stat Bite: Use of mammography by age group, 1990–2000, Jan. 2, p. 11
Allylaminogeldanamycin (17AAG)
Heat shock protein inhibitor shows antitumor activity, Aug. 21, p. 1194
Alternative medicine, *see* **Complementary and alternative medicine**
American Association of Cancer Research (AACR)
Whatever happened to … ? Looking back 10 years, Nov. 6, p. 1600
American BioSciences Inc.
Battle over generic Taxol concludes, but controversy continues, Mar. 6, p. 324
American Society of Clinical Oncology
Big business: When Wall Street and cancer research collide, Sept. 18, p. 1352
Whatever happened to … ? Looking back 10 years, Nov. 6, p. 1600
Anaphase promoting complex (APC)
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Anastrozole
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Angiogenesis
Despite checkered past, thalidomide and its analogues show potential, Sept. 4, p. 1270
First clinical trials of endostatin yield lukewarm results, Oct. 16, p. 1520
Researchers explore role of gene transfer in tumor growth, Mar. 20, p. 413
APC mutations
Stool test identifies markers for colorectal cancer, studies show, Mar. 6, p. 332
Appalachia
Program aims to reduce cancer burden in Appalachia, Aug. 21, p. 1189
Stat Bite: Lung cancer death rates in Appalachia, 1994–1998, Aug. 21, p. 1190
Arimidex, *see* **Anastrozole**
Aromatase inhibitors
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Asia
Stat Bite: Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p. 1428
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426
AstraZeneca
AstraZeneca reprimanded for Nolvadex advertisement, Mar. 6, p. 330
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
Ataxia telangiectasia
Consortium piecing together role of ATM gene in breast cancer, Feb. 6, p. 158
Australia
Stat Bite: Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p. 1428
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426

Bethesda System
New Pap test terminology, management guidelines published, June 19, p. 878
Bexxar
For Bexxar, FDA meeting offers long-awaited chance at approval, Dec. 4, p. 1738
Bioengineering
New imaging institute focuses its goals, plans for future, Sept. 18, p. 1355
Biologic samples
Consent, privacy concerns cloud future of biologic sampling, Oct. 2, p. 1429
Biotechnology
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
Bioterrorism
Congress considers stockpiling potassium iodide, Jan. 16, p. 86
Bladder cancer
Studies expand potential uses of photodynamic therapy, Dec. 4, p. 1740
Brachytherapy
New treatments target metastatic tumors in liver, Feb. 6, p. 164
Brain tumors
Studies expand potential uses of photodynamic therapy, Dec. 4, p. 1740
BRCA1/2
French challenge to BRCA1 patent underlies European discontent, Jan. 16, p. 80
Breast cancer
After Long Island study, advocates look for a stronger voice, Sept. 18, p. 1349
Cardiotoxicity concerns prompt data review in breast cancer trial, May 1, p. 650
Consortium piecing together role of ATM gene in breast cancer, Feb. 6, p. 158
The end of an era? Study reveals harms of hormone replacement therapy, Aug. 7, p. 1116
Long Island study finds no link between pollutants and breast cancer, Sept. 18, p. 1348
Researchers push for sharing of trial results with participants, July 17, p. 1049
Stat Bite: Breast cancer incidence in New York State, 1993–1997, Sept. 18, p. 1350
Stat Bite: Breast cancer mortality rates in selected countries, 1951–1997, Mar. 20, p. 412
Stat Bite: Breast cancer stage distribution, 1998, Jan. 16, p. 83
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Stat Bite: Incidence of and mortality from breast cancer, 1973–1999, Oct. 16, p. 1524
Task force urges doctors to discuss breast cancer prevention, Aug. 7, p. 1121

Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Breast-conserving therapy
Use of breast-conserving therapy increases, but variations persist, Apr. 3, p. 480
Bristol-Myers Squibb
Battle over generic Taxol concludes, but controversy continues, Mar. 6, p. 324
Erbitux trial flawed from the beginning, committee finds, Dec. 18, p. 1824
Business
Big business: When Wall Street and cancer research collide, Sept. 18, p. 1352

Canada
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
Cancer Information Service
Cancer Information Service celebrates silver anniversary, Jan. 16, p. 84
Cancer Staging Manual, *see* **Staging**
Cancer Therapeutics Research Group (CTRG)
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426
Cardiotoxicity
Cardiotoxicity concerns prompt data review in breast cancer trial, May 1, p. 650
Care, *see* **Health care**
Celecoxib
COX-2 inhibitors: Cancer trials test new uses for pain drug, Feb. 20, p. 248
Cell migration
Movies of metastasis shed light on how cells move in the body, June 5, p. 795
Cervical cancer
Developing countries put cervical cancer tests to the test, Feb. 20, p. 245
Stat Bite: Frequency of cervical cancer screening by age group, 2000, June 19, p. 879
Stat Bite: Estimated cervical cancer mortality in selected countries, 2000, Feb. 20, p. 246
see also **Pap tests**
Cetuximab
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
Despite concerns, FDA panel backs EGFR inhibitor, Nov. 6, p. 1596
Erbitux trial flawed from the beginning, committee finds, Dec. 18, p. 1824
Chemoprevention
Retinoids and lung cancer: Targeting the right population, July 3, p. 969
Task force urges doctors to discuss breast cancer prevention, Aug. 7, p. 1121
Chemoresistance, *see* **Drug resistance**
Chemotherapy
Aerosolized chemotherapy? Inhalation therapy gains ground, Apr. 17, p. 556
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients, Nov. 20, p. 1670
Could less be more? Low-dose chemotherapy goes on trial, Jan. 16, p. 82
Counterfeit cases set stage for today's laws, safety mechanisms, Oct. 2, p. 1425
Despite concerns, FDA panel backs EGFR inhibitor, Nov. 6, p. 1596
FDA evaluating oxaliplatin for advanced colorectal cancer treatment, Aug. 21, p. 1191
Gene profiles may help predict response to chemotherapy, July 17, p. 1052
Is there less resistance on the chemoresistance front? Jan. 2, p. 15
Children
Cancer survivors still struggle to get adequate follow-up care, May 15, p. 714
Cigarettes
'Light' cigarettes offer no benefit to smokers, report says, Feb. 6, p. 162
New cigarette advertisements reignite debate on safety, Feb. 6, p. 160
see also **Tobacco**
Clinical trials
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
COX-2 inhibitors: Cancer trials test new uses for pain drug, Feb. 20, p. 248
Despite checkered past, thalidomide and its analogues show potential, Sept. 4, p. 1270
Erbitux trial flawed from the beginning, committee finds, Dec. 18, p. 1824
For institutional review boards, decisions can be subjective, Oct. 16, p. 1518
Initiative to focus on boosting enrollment in clinical trials, Aug. 21, p. 1195
Recruitment begins for lung cancer screening trial, Nov. 6, p. 1603
Researchers push for sharing of trial results with participants, July 17, p. 1049
Vagaries of research publishing again under the microscope, July 3, p. 964
Would central review streamline the process? Oct. 16, p. 1519
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426
Collaboration
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426
Colorectal cancer
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
FDA evaluating oxaliplatin for advanced colorectal cancer treatment, Aug. 21, p. 1191
New treatments target metastatic tumors in liver, Feb. 6, p. 164
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Stool test identifies markers for colorectal cancer, studies show, Mar. 6, p. 332
Compensation
Government sets compensation guidelines for radiation exposure, June 5, p. 797
Complementary and alternative medicine
Contamination of PC-SPES remains a mystery, Sept. 4, p. 1266
Stat Bite: Use of complementary and alternative medicine among cancer patients, May 1, p. 648
Tests of three herbal therapies yield disappointing results, May 1, p. 649
Whatever happened to…? Looking back 10 years, Nov. 6, p. 1600
White House report on alternative medicine draws criticism, May 1, p. 646
Conflicts of interest
Vagaries of research publishing again under the microscope, July 3, p. 964
Consolidated Standards of Reporting Trials (CONSORT)
Vagaries of research publishing again under the microscope, July 3, p. 964

Counterfeit drugs
Counterfeit cases set stage for today's laws, safety mechanisms, Oct. 2, p. 1425
Increase in drug tampering reports sparks new security considerations, Oct. 2, p. 1424
COX-2 inhibitors
COX-2 inhibitors: Cancer trials test new uses for pain drug, Feb. 20, p. 248
CPT-11, *see* **Irinotecan**
Cromatin
Silence of the genes: Cancer epigenetics arrives, June 5, p. 793

Data sharing
NIH seeks comment on proposed data sharing policy, Apr. 17, p. 555
When scientists don't share: Is secrecy a necessary evil? May 15, p. 712
Depression
Cancer care should include symptom management, panel says, Aug. 7, p. 1123
Developing countries
Developing countries put cervical cancer tests to the test, Feb. 20, p. 245
Diet
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
Diethylstilbestrol (DES)
Contamination of PC-SPES remains a mystery, Sept. 4, p. 1266
Disease classification
Health agencies adopt new disease classification codes, May 15, p. 710
Updates to staging system reflect advances in imaging, understanding, Nov. 20, p. 1664
DNA methylation
Breaking the silence: The rise of epigenetic therapy, June 19, p. 874
Drug resistance
Is there less resistance on the chemoresistance front? Jan. 2, p. 15
Drug tampering
Counterfeit cases set stage for today's laws, safety mechanisms, Oct. 2, p. 1425
Increase in drug tampering reports sparks new security considerations, Oct. 2, p. 1424

Endostatin
First clinical trials of endostatin yield lukewarm results, Oct. 16, p. 1520
Epidemiology
Guilt by association? Some cancer epidemiology favorites, Dec. 18, p. 1826
Epidermal growth factor receptor
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
Despite concerns, FDA panel backs EGFR inhibitor, Nov. 6, p. 1596
Epigenetics
Silence of the genes: Cancer epigenetics arrives, June 5, p. 793
Erbitux, *see* **Cetuximab**
Esophageal cancer
Stat Bite: Mortality from esophageal cancer in selected countries, 1998, Apr. 3, p. 477
Estrogen therapy, *see* **Hormone replacement therapy**
Ethics
Consent, privacy concerns cloud future of biologic sampling, Oct. 2, p. 1429
Europe
French challenge to BRCA1 patent underlies European discontent, Jan. 16, p. 80

Familial adenomatous polyposis (FAP)
COX-2 inhibitors: Cancer trials test new uses for pain drug, Feb. 20, p. 248
Fatigue
Cancer care should include symptom management, panel says, Aug. 7, p. 1123
FOLFOX4
FDA evaluating oxaliplatin for advanced colorectal cancer treatment, Aug. 21, p. 1191
France
French challenge to BRCA1 patent underlies European discontent, Jan. 16, p. 80
Fruit
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
Fulvestrant
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Fungal antibiotics
Heat shock protein inhibitor shows antitumor activity, Aug. 21, p. 1194
Gastrointestinal cancers
Studies expand potential uses of photodynamic therapy, Dec. 4, p. 1740
Gene therapy
Breaking the silence: The rise of epigenetic therapy, June 19, p. 874
A one-two punch: Light-based therapy finds tumors, delivers treatment, Sept. 4, p. 1272 (correction: Oct. 2, p. 1432)
Generic drugs
Battle over generic Taxol concludes, but controversy continues, Mar. 6, p. 324
Genes
Consortium piecing together role of ATM gene in breast cancer, Feb. 6, p. 158
Gene profiles may help predict response to chemotherapy, July 17, p. 1052
Mutation analysis suggests role for ribonuclease L gene in prostate cancer, Feb. 20, p. 244 (correction: Apr. 3, p. 481)
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Researchers explore role of gene transfer in tumor growth, Mar. 20, p. 413
Silence of the genes: Cancer epigenetics arrives, June 5, p. 793
SNPs: Can genetic variants control cancer susceptibility? Apr. 3, p. 476
Stool test identifies markers for colorectal cancer, studies show, Mar. 6, p. 332
Genotype
SNPs: Can genetic variants control cancer susceptibility? Apr. 3, p. 476
Gleevec, *see* **Imatinib**
Great Britain, *see* **United Kingdom**
Green tea
Tests of three herbal therapies yield disappointing results, May 1, p. 649
Group C
Demand grows for early access to promising cancer drugs, Nov. 20, p. 1668
Guidelines
Guidelines for abnormal Pap tests: Do physicians follow them? June 19, p. 880
New Pap test terminology, management guidelines published, June 19, p. 878

Hanford Nuclear Site
Final report of Hanford Thyroid Disease Study released, July 17, p. 1046

Stat Bite: Occurrence of thyroid cancer in the Hanford Thyroid Disease Study, July 17, p. 1048
Head and neck cancer
Studies expand potential uses of photodynamic therapy, Dec. 4, p. 1740
Health care
Cancer care should include symptom management, panel says, Aug. 7, p. 1123
Cancer survivors still struggle to get adequate follow-up care, May 15, p. 714
Networks aim to bridge gap between clinical research, medical practice, Apr. 3, p. 478
Presidential panel calls for overhaul in cancer care, Jan. 16, p. 84
Reinvestment Act may provide relief for nursing shortage, Sept. 18, p. 1354
U.K.'s efforts to improve multidisciplinary care criticized, Feb. 6, p. 163
Health Insurance Portability and Accountability Act (HIPAA)
Final regulations set for patient privacy protection, Oct. 16, p. 1521
Health insurance
Entire family faces consequences of lack of insurance, report finds, Nov. 6, p. 1601
For the uninsured, health problems are more serious, July 3, p. 967
Insurers, employers ask for better evaluation of new technologies, Feb. 20, p. 250
Stat Bite: Estimated excess deaths among uninsured adults, 2000, July 3, p. 968
Health policy
When scientists don't share: Is secrecy a necessary evil? May 15, p. 712
Heat shock protein inhibitor
Heat shock protein inhibitor shows antitumor activity, Aug. 21, p. 1194
Heat shock protein vaccine
Heat shock protein vaccine: How does it work? Jan. 2, p. 13
Heat shock protein vaccine: Producing an immune response in mice and men, Jan. 2, p. 12
Hepatitis C
Can increased treatment of hepatitis C stem the tide of liver cancer? July 17, p. 1050
Herceptin, *see* **Trastuzumab**
High-intensity focused ultrasound (HIFU)
High-intensity focused ultrasound makes its debut, July 3, p. 962
Will less drastic procedures replace radical prostatectomy? July 3, p. 963
Histone deacetylase inhibitors (HDAC)
Breaking the silence: The rise of epigenetic therapy, June 19, p. 874
History
National Cancer Act: Leaders reflect on 30 years of progress, Jan. 2, p. 8
Thirty years ago, efforts to remove NCI from NIH failed, Jan. 2, p. 9
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
Whatever happened to…? Looking back 10 years, Nov. 6, p. 1600
Hong Kong
Stat Bite: Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p. 1428
Horizontal Gene Transfer
Researchers explore role of gene transfer in tumor growth, Mar. 20, p. 413
Hormone replacement therapy
The end of an era? Study reveals harms of hormone replacement therapy, Aug. 7, p. 1116
Menopause is 'by no means confined to the woman,' doctor said, Aug. 7, p. 1117
Stat Bite: Disease rates in a study of combination hormone replacement therapy, Aug. 7, p. 1118
Human papillomavirus (HPV)
Developing countries put cervical cancer tests to the test, Feb. 20, p. 245
Human embryonic stem cells
Research update: Neural cells cultured from stem cells, Jan. 16, p. 87

Imaging
New imaging institute focuses its goals, plans for future, Sept. 18, p. 1355
Updates to staging system reflect advances in imaging, understanding, Nov. 20, p. 1664
Imatinib
Collaboration to play key role in NCI's future, director says, June 5, p. 790
Synthetic lethality: Killing cancer with cancer, Nov. 20, p. 1666
IMC-C225, *see* **Cetuximab**
ImClone Systems Inc.
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
Erbitux trial flawed from the beginning, committee finds, Dec. 18, p. 1824
Immune system
Cancer vaccines: Finding the best way to train the immune system, Oct. 16, p. 1523
Melanoma treatment activates immune system against cancer, Dec. 4, p. 1743
Immunotherapy
For Bexxar, FDA meeting offers long-awaited chance at approval, Dec. 4, p. 1738
Incidence
New uniform population standard better reflects U.S. cancer burden, May 15, p. 708
Stat Bite: Cancer incidence and mortality with and without lung cancer, 1973–1998, Apr. 17, p. 554
Stat Bite: Incidence of cancers of the eye and orbit, 1995–1999, Dec. 18, p. 1828
Stat Bite: Incidence of and mortality from breast cancer, 1973–1999, Oct. 16, p. 1524
Stat Bite: Incidence of and mortality from lung and bronchus cancer, 1973–1999, June 5, p. 794
Stat Bite: Pancreatic cancer incidence in U.S. blacks and whites, 1973–1999, Nov. 20, p. 1671
Informed consent
Cancer registries: Should informed consent be required? Sept. 4, p. 1269
Consent, privacy concerns cloud future of biologic sampling, Oct. 2, p. 1429
Inhalation therapy
Aerosolized chemotherapy? Inhalation therapy gains ground, Apr. 17, p. 556
Institute of Medicine
Entire family faces consequences of lack of insurance, report finds, Nov. 6, p. 1601
For the uninsured, health problems are more serious, July 3, p. 967
Insurers, employers ask for better evaluation of new technologies, Feb. 20, p. 250
Networks aim to bridge gap between clinical research, medical practice, Apr. 3, p. 478
Presidential panel calls for overhaul in cancer care, Jan. 16, p. 84
Institutional review boards
For institutional review boards, decisions can be subjective, Oct. 16, p. 1518
Would central review streamline the clinical trials process? Oct. 16, p. 1519

Insurance, *see* **Health insurance**
Interleukin 2
Aerosolized chemotherapy? Inhalation therapy gains ground, Apr. 17, p. 556
Melanoma treatment activates immune system against cancer, Dec. 4, p. 1743
International Classification of Diseases and Related Health Problems
Health agencies adopt new disease classification codes, May 15, p. 710
Investigational New Drugs
Demand grows for early access to promising cancer drugs, Nov. 20, p. 1668
Iodine 131 tositumomab, *see* **Bexxar**
Iressa
Despite concerns, FDA panel backs EGFR inhibitor, Nov. 6, p. 1596
Irinotecan
Biotech firm faces challenges from FDA, falling stock prices, Mar. 6, p. 326
FDA evaluating oxaliplatin for advanced colorectal cancer treatment, Aug. 21, p. 1191
Tests of three herbal therapies yield disappointing results, May 1, p. 649
Ivax Pharmaceuticals
Battle over generic Taxol concludes, but controversy continues, Mar. 6, p. 324

Leukemia
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Light-based therapy
A one-two punch: Light-based therapy finds tumors, delivers treatment, Sept. 4, p. 1272 (correction: Oct. 2, p. 1432)
Liver cancer
Can increased treatment of hepatitis C stem the tide of liver cancer? July 17, p. 1050
New treatments target metastatic tumors in liver, Feb. 6, p. 164
Long Island, *see* **New York**
Lung cancer
Despite concerns, FDA panel backs EGFR inhibitor, Nov. 6, p. 1596
Recruitment begins for lung cancer screening trial, Nov. 6, p. 1603
Retinoids and lung cancer: Targeting the right population, July 3, p. 969
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Stat Bite: Lung cancer death rates in Appalachia, 1994–1998, Aug. 21, p. 1190
Stat Bite: Incidence of and mortality from lung and bronchus cancer, 1973–1999, June 5, p. 794
Lymphoma
Gene profiles may help predict response to chemotherapy, July 17, p. 1052
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328

Mammography
Mammography guidelines in the national spotlight … again, Mar. 20, p. 411
Stat Bite: Use of mammography by age group, 1990–2000, Jan. 2, p. 11
See also **Screening**
Marketing
AstraZeneca reprimanded for Nolvadex advertisement, Mar. 6, p. 330
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
New cigarette advertisements reignite debate on safety, Feb. 6, p. 160
Pharmaceutical companies adopt new guidelines for marketing, Aug. 7, p. 1119
Mdm2
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Melanoma
Melanoma treatment activates immune system against cancer, Dec. 4, p. 1743
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Menopause
Menopause is 'by no means confined to the woman,' doctor said, Aug. 7, p. 1117
Metastasis
Movies of metastasis shed light on how cells move in the body, June 5, p. 795
New treatments target metastatic tumors in liver, Feb. 6, p. 164
A one-two punch: Light-based therapy finds tumors, delivers treatment, Sept. 4, p. 1272 (correction: Oct. 2, p. 1432)
Mortality
Stat Bite: Breast cancer mortality rates in selected countries, 1951–1997, Mar. 20, p. 412
Stat Bite: Cancer deaths in the United States attributable to smoking, 1995–1999, Sept. 4, p. 1268
Stat Bite: Cancer incidence and mortality with and without lung cancer, 1973–1998, Apr. 17, p. 554
Stat Bite: Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p 1428
Stat Bite: Cancer mortality rates age-adjusted by different age standards, 1973–1999, May 15, p. 711
Stat Bite: Incidence of and mortality from breast cancer, 1973–1999, Oct. 16, p. 1524
Stat Bite: Incidence of and mortality from lung and bronchus cancer, 1973–1999, June 5, p. 794
Stat Bite: Mortality from esophageal cancer in selected countries, 1998, Apr. 3, p. 477
Multiple myeloma
Despite checkered past, thalidomide and its analogues show potential, Sept. 4, p. 1270
Mutation
Mutation analysis suggests role for ribonuclease L gene in prostate cancer, Feb. 20, p. 244 (correction: Apr. 3, p. 481)
Synthetic lethality: Killing cancer with cancer, Nov. 20, p. 1666
see also **Genes**

National Cancer Act
Legislators rally for support of revised National Cancer Act, Mar. 20, p. 410
National Cancer Act: Leaders reflect on 30 years of progress, Jan. 2, p. 8
Thirty years ago, efforts to remove NCI from NIH failed, Jan. 2, p. 9
National Center for Health Statistics
Health agencies adopt new disease classification codes, May 15, p. 710
National Institute of Biomedical Imaging and Bioengineering
New imaging institute focuses its goals, plans for future, Sept. 18, p. 1355
National Surgical Adjuvant Breast and Bowel Project
Researchers push for sharing of trial results with participants, July 17, p. 1049
National Translational Cancer Research Network
U.K. initiative to boost translational research, May 15, p. 715
Neural cells
Research update: Neural cells cultured from stem cells, Jan. 16, p. 87

New York
After Long Island study, advocates look for a stronger voice, Sept. 18, p. 1349
Long Island study finds no link between pollutants and breast cancer, Sept. 18, p. 1348
Stat Bite: Breast cancer incidence in New York State, 1993–1997, Sept. 18, p. 1350
New Zealand
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
Nolvadex, *see* **Tamoxifen**
Non-Hodgkin's lymphoma
For Bexxar, FDA meeting offers long-awaited chance at approval, Dec. 4, p. 1738
Nuclear sites
Final report of Hanford Thyroid Disease Study released, July 17, p. 1046
Stat Bite: Occurrence of thyroid cancer in the Hanford Thyroid Disease Study, July 17, p. 1048
Nursing
Reinvestment Act may provide relief for nursing shortage, Sept. 18, p. 1354

Ocular Cancer
Designer molecule may lead to new treatments for ocular cancers, Dec. 18, p. 1827
Stat Bite: Incidence of cancers of the eye and orbit, 1995–1999, Dec. 18, p. 1828
Office of Alternative Medicine
Whatever happened to…? Looking back 10 years, Nov. 6, p. 1600
Oxaliplatin
FDA evaluating oxaliplatin for advanced colorectal cancer treatment, Aug. 21, p. 1191
Paclitaxel
Battle over generic Taxol concludes, but controversy continues, Mar. 6, p. 324
Cardiotoxicity concerns prompt data review in breast cancer trial, May 1, p. 650
Pain
Cancer care should include symptom management, panel says, Aug. 7, p. 1123
Palliative care
U.K. initiative aims to broaden definition of palliative care, Oct. 2, p. 1431
Pancreatic cancer
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients, Nov. 20, p. 1670
Stat Bite: Pancreatic cancer incidence in U.S. blacks and whites, 1973–1999, Nov. 20, p. 1671
Pap tests
Developing countries put cervical cancer tests to the test, Feb. 20, p. 245
Stat Bite: Frequency of cervical cancer screening by age group, 2000, June 19, p. 879
Guidelines for abnormal Pap tests: Do physicians follow them? June 19, p. 880
New Pap test terminology, management guidelines published, June 19, p. 878
see also **Screening**
Patents
French challenge to BRCA1 patent underlies European discontent, Jan. 16, p. 80
PC-SPES
Tests of three herbal therapies yield disappointing results, May 1, p. 649
Contamination of PC-SPES remains a mystery, Sept. 4, p. 1266
Peptide nucleic acid
RNA-based therapy unlocks drugs within cancer cells, Dec. 18, p. 1829
Pharmaceutical industry
Investing in prevention: What incentive does the pharmaceutical industry have? Dec. 4, p. 1736
Menopause is 'by no means confined to the woman,' doctor said, Aug. 7, p. 1117
Pharmaceutical companies adopt new guidelines for marketing, Aug. 7, p. 1119
Photodynamic therapy (PDT)
Studies expand potential uses of photodynamic therapy, Dec. 4, p. 1740
Pollution
Acrylamide and cancer: Tunnel leak in Sweden prompted studies, June 19, p. 876
Long Island study finds no link between pollutants and breast cancer, Sept. 18, p. 1348
Polycyclic aromatic hydrocarbons (PAH)
After Long Island study, advocates look for a stronger voice, Sept. 18, p. 1349
Long Island study finds no link between pollutants and breast cancer, Sept. 18, p. 1348
Population standard
New uniform population standard better reflects U.S. cancer burden, May 15, p. 708
Potassium iodide
Congress considers stockpiling potassium iodide, Jan. 16, p. 86
Prevention
COX-2 inhibitors: Cancer trials test new uses for pain drug, Feb. 20, p. 248
Investing in prevention: What incentive does the pharmaceutical industry have? Dec. 4, p. 1736
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
Privacy
Final regulations set for patient privacy protection, Oct. 16, p. 1521
Prostate cancer
Contamination of PC-SPES remains a mystery, Sept. 4, p. 1266
High-intensity focused ultrasound makes its debut, July 3, p. 962
Mutation analysis suggests role for ribonuclease L gene in prostate cancer, Feb. 20, p. 244 (correction: Apr. 3, p. 481)
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Will less drastic procedures replace radical prostatectomy? July 3, p. 963
Prostate-specific antigen (PSA)
Value of prostate-specific antigen: Are higher levels meaningful? Mar. 20, p. 415
Whatever happened to…? Looking back 10 years, Nov. 6, p. 1600
Proteomics
For proteomics research, a new race has begun, Apr. 17, p. 552
PS-341
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Public health
Program aims to reduce cancer burden in Appalachia, Aug. 21, p. 1189
Publishing
Vagaries of research publishing again under the microscope, July 3, p. 964

Quality of care
Use of breast-conserving therapy increases, but variations persist, Apr. 3, p. 480

Race and ethnicity
Young cooperative oncology group spans Southeast Asia, Australia, Oct. 2, p. 1426
Radiation
Final report of Hanford Thyroid Disease Study released, July 17, p. 1046
Government sets compensation guidelines for radiation exposure, June 5, p. 797
Stat Bite: Occurrence of thyroid cancer in the Hanford Thyroid Disease Study, July 17, p. 1048
Radiofrequency ablation (RFA)
New treatments target metastatic tumors in liver, Feb. 6, p. 164
Radiotherapy
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients, Nov. 20, p. 1670
Raloxifene
Task force urges doctors to discuss breast cancer prevention, Aug. 7, p. 1121
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Registries
Cancer registries: Should informed consent be required? Sept. 4, p. 1269
Research
Big business: When Wall Street and cancer research collide, Sept. 18, p. 1352
Initiative to focus on boosting enrollment in clinical trials, Aug. 21, p. 1195
Networks aim to bridge gap between clinical research, medical practice, Apr. 3, p. 478
Neural cells cultured from stem cells, Jan. 16, p. 87
U.K. initiative to boost translational research, May 15, p. 715
Vagaries of research publishing again under the microscope, July 3, p. 964
When scientists don't share: Is secrecy a necessary evil? May 15, p. 712
Retinoids
Retinoids and lung cancer: Targeting the right population, July 3, p. 969
Review
For institutional review boards, decisions can be subjective, Oct. 16, p. 1518
Would central review streamline the clinical trials process? Oct. 16, p. 1519
Risk
Guilt by association? Some cancer epidemiology favorites, Dec. 18, p. 1826
RNA
RNA-based therapy unlocks drugs within cancer cells, Dec. 18, p. 1829

Screening
Developing countries put cervical cancer tests to the test, Feb. 20, p. 245
Mammography guidelines in the national spotlight … again, Mar. 20, p. 411
New Pap test terminology, management guidelines published, June 19, p. 878
Recruitment begins for lung cancer screening trial, Nov. 6, p. 1603
Stat Bite: Frequency of cervical cancer screening by age group, 2000, June 19, p. 879
Stat Bite: Use of mammography by age group, 1990–2000, Jan. 2, p. 11
Selective estrogen receptor modulators (SERMs)
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Singapore
Stat Bite: Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p. 1428
Single nucleotide polymorphisms
SNPs: Can genetic variants control cancer susceptibility? Apr. 3, p. 476
Skp2
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Smoking, *see* **Tobacco**
St. John's wort
Tests of three herbal therapies yield disappointing results, May 1, p. 649
Staging
Updates to staging system reflect advances in imaging, understanding, Nov. 20, p. 1664
Stat Bites
Breast cancer incidence in New York State, 1993–1997, Sept. 18, p. 1350
Breast cancer mortality rates in selected countries, 1951–1997, Mar. 20, p. 412
Breast cancer stage distribution, 1998, Jan. 16, p. 83
Cancer deaths in the United States attributable to smoking, 1995–1999, Sept. 4, p. 1268
Cancer mortality in males in Australia, Hong Kong, and Singapore, 1996, Oct. 2, p. 1428
Cancer mortality rates age-adjusted by different age standards, 1973–1999, May 15, p. 711
Disease rates in a study of combination hormone replacement therapy, Aug. 7, p. 1118
Estimated cervical cancer mortality in selected countries, 2000, Feb. 20, p. 246
Estimated excess deaths among uninsured adults, 2000, July 3, p. 968
Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328
Frequency of cervical cancer screening by age group, 2000, June 19, p. 879
Designer molecule may lead to new treatments for ocular cancers, Dec. 18, p. 1827
Incidence of and mortality from breast cancer, 1973–1999, Oct. 16, p. 1524
Incidence of and mortality from lung and bronchus cancer, 1973–1999, June 5, p. 794
Lung cancer death rates in Appalachia, 1994–1998, Aug. 21, p. 1190
Mortality from esophageal cancer in selected countries, 1998, Apr. 3, p. 477
Occurrence of thyroid cancer in the Hanford Thyroid Disease Study, July 17, p. 1048
Smoking prevalence among U.S. adults, 1990–2000, Feb. 6, p. 161
States' allocation of tobacco settlement revenue, 2000 and 2001, Nov. 6, p. 1599
Use of complementary and alternative medicine among cancer patients, May 1, p. 648
Use of mammography by age group, 1990–2000, Jan. 2, p. 11
Statistics
Common terms used in cancer statistics, May 15, p. 709
Health agencies adopt new disease classification codes, May 15, p. 710
New uniform population standard better reflects U.S. cancer burden, May 15, p. 708
See also **Stat Bites**
Stem cells
Research update: Neural cells cultured from stem cells, Jan. 16, p. 87
Survivors
Cancer survivors still struggle to get adequate follow-up care, May 15, p. 714

Sweden
Acrylamide and cancer: Tunnel leak in Sweden prompted studies, June 19, p. 876
Symptoms
Cancer care should include symptom management, panel says, Aug. 7, p. 1123
Synthetic lethality
Synthetic lethality: Killing cancer with cancer, Nov. 20, p. 1666

Tamoxifen
AstraZeneca reprimanded for Nolvadex advertisement, Mar. 6, p. 330
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
FDA issues warning about 'new' tamoxifen risk, Aug. 7, p. 1122
Researchers push for sharing of trial results with participants, July 17, p. 1049
Task force urges doctors to discuss breast cancer prevention, Aug. 7, p. 1121
Upstaging tamoxifen? New classes of drugs emerging for breast cancer, Apr. 3, p. 474 (correction: May 15, p. 717)
Taxol, *see* **Paclitaxel**
Terminology
Common terms used in cancer statistics, May 15, p. 709
New Pap test terminology, management guidelines published, June 19, p. 878
Thalidomide
Despite checkered past, thalidomide and its analogues show potential, Sept. 4, p. 1270
Thyroid cancer
Congress considers stockpiling potassium iodide, Jan. 16, p. 86
Final report of Hanford Thyroid Disease Study released, July 17, p. 1046
Stat Bite: Occurrence of thyroid cancer in the Hanford Thyroid Disease Study, July 17, p. 1048
TNM
Updates to staging system reflect advances in imaging, understanding, Nov. 20, p. 1664
Tobacco
'Light' cigarettes offer no benefit to smokers, report says, Feb. 6, p. 162
New cigarette advertisements reignite debate on safety, Feb. 6, p. 160
Retinoids and lung cancer: Targeting the right population, July 3, p. 969
Stat Bite: Cancer deaths in the United States attributable to smoking, 1995–1999, Sept. 4, p. 1268
Stat Bite: Smoking prevalence among U.S. adults, 1990–2000, Feb. 6, p. 161
Stat Bite: States' allocation of tobacco settlement revenue, 2000 and 2001, Nov. 6, p. 1599
Tobacco programs wither as states divert settlement revenue, Nov. 6, p. 1598
World Health Organization takes on 'tobacco epidemic,' May 1, p. 644
Translational research
U.K. initiative to boost translational research, May 15, p. 715
Trastuzumab
Cardiotoxicity concerns prompt data review in breast cancer trial, May 1, p. 650
Tylenol
Counterfeit cases set stage for today's laws, safety mechanisms, Oct. 2, p. 1425

Ubiquitin
On the eve of protein destruction: Ubiquitin research begins to pay off, Apr. 17, p. 550
Ultrasound
High-intensity focused ultrasound makes its debut, July 3, p. 962
Will less drastic procedures replace radical prostatectomy? July 3, p. 963
Unapproved drugs
Demand grows for early access to promising cancer drugs, Nov. 20, p. 1668
Uninsured patients
For the uninsured, health problems are more serious, July 3, p. 967
Stat Bite: Estimated excess deaths among uninsured adults, 2000, July 3, p. 968
United Kingdom
U.K. initiative aims to broaden definition of palliative care, Oct. 2, p. 1431
U.K. initiative to boost translational research, May 15, p. 715
U.K.'s efforts to improve multidisciplinary care criticized, Feb. 6, p. 163
United States
Direct-to-consumer marketing: How has it fared? Mar. 6, p. 329
New uniform population standard better reflects U.S. cancer burden, May 15, p. 708
Stat Bite: Cancer deaths in the United States attributable to smoking, 1995–1999, Sept. 4, p. 1268
Stat Bite: Estimated new cases of selected cancers in the United States, 2002, Mar. 6, p. 328

Vaccines
Cancer vaccines: Finding the best way to train the immune system, Oct. 16, p. 1523
Heat shock protein vaccine: How does it work? Jan. 2, p. 13
Heat shock protein vaccine: Producing an immune response in mice and men, Jan. 2, p. 12
Vegetables
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
Vitamins
Whatever happened to…? Looking back 10 years, Jan. 2, p. 10
von Eschenbach, Andrew
Collaboration to play key role in NCI's future, director says, June 5, p. 790
Urologic surgeon to head National Cancer Institute, Jan. 2, p. 16

Water
Acrylamide and cancer: Tunnel leak in Sweden prompted studies, June 19, p. 876
White House Commission on Complementary and Alternative Medicine Policy
White House report on alternative medicine draws criticism, May 1, p. 646
World Health Organization
World Health Organization takes on 'tobacco epidemic,' May 1, p. 644

ZD1839, *see* **Iressa**

SUBJECT INDEX

Aberrant signaling, tumorigenesis, human herpesvirus-8, and K1 gene, 926 [mice]
Access to care, racial/ethnic disparities, 353
Adenovirus-based gene therapy, ovarian cancer, noninvasive imaging, 706 (editorial), 741 [mice]
Adherence, 652, 1652 (correspondence)
Adjuvant therapy
breast cancer, and tamoxifen, trends, 1626
breast cancer, HER2 assays, 788 (editorial), 852
breast cancer, postmenopausal lymph node-negative, 1041 (editorial), 1054, 1339 (*erratum*)
colon cancer, African-Americans and Caucasians, 1160
colorectal cancer, NSAIDs, 259
racial/ethnic disparities, adjuvant radiation therapy, 339
Adrenomedullin, breast cancer, 1226 [cell lines]
Affect, psychological therapies, 563, 1810 (correspondence)
Africa, AIDS-related non-Hodgkin's lymphoma, U.S. and East Africa, 718
African-Americans
colon cancer, adjuvant chemotherapy, 1160
non-small-cell lung cancer, 284
Age
colorectal cancer, second primary cancer, 529 (correspondence)
HPV testing, and atypical squamous cells of undetermined significance (ASCUS), 102
Kaposi's sarcoma, human herpesvirus 8, elderly males, 1333
tamoxifen, estrogen, and brain metabolism, elderly women, 547 (editorial), 592, 1336 (correspondence)
Agnoprotein, medulloblastoma and JCV polyomavirus, 240 (editorial), 267
AIDS-related non-Hodgkin's lymphoma, U.S. and East Africa, 718
Air pollution, lung cancer, household stove improvement, China, 826
Akt signaling pathways, prostate cancer, cyclooxygenase-2 inhibitors, prevention, 1732 (editorial), 1745 [cell lines]
Alcohol consumption, lung cancer risk and, 1877
Allium vegetables, prostate cancer and, 1648
Androgen deprivation therapy, prostate cancer, and quality of life, 407 (editorial), 430
Androgen receptors, prostate cancer, methylation and inactivation, 384 [cell lines]
Anemia, chemotherapy-associated, lung cancer, darbepoetin alfa and, 1184 (editorial), 1211
Anethole dithiolethione, lung cancer, chemoprevention in smokers, 1001
Angiogenesis
GcMAF, 1311 [cell lines]
ovarian cancer, stromal therapy, 1113 (editorial), 1134 [mice]
Antiangiogenic antibodies
clinical application, 883
HuMV833, solid tumors, molecular imaging and biological evaluation, 1484
Antiperspirant use, breast cancer risk and, 1578
Anxiety, psychological therapies, 563, 1810 (correspondence)
Apoptosis
breast cancer and estrogen deprivation, 1173 [cell lines] (correspondence)
CD40-mediated, urothelial cells, 1381 [cell lines]
3D reconstituted basement membrane assay, 1494 [cell lines], 1894 (*erratum*)
leukemia, interleukin 8, CD13/aminopeptidase N, and apoptosis mediated by endothelial cells, 1020 [cell lines]
neuroblastoma, ras expression and caspase-independent cell death, 319 (editorial), 358
NSAIDs, 257
ovary, progestin-induced, and transforming growth factor-β, 50 [macaque]
pancreatic cancer, chemotherapy-induced, and pRB expression, 129
prostate cancer, COS-2, 545 (editorial), 585
RNA and polo-like kinase-1, 1863 [cell lines]
vanilloid-induced, 1263 (editorial), 1281 [cell lines]
Arf, melanocyte senescence and differentiation, 446 [mice], 866 (*erratum*)
Arsenic
bladder cancer, arsenic-related chromosomal alterations and, 1688
prostate cancer, arsenic-induced malignant transformation, 1888 [cell lines]
Aspirin
cardiovascular events prevention, 253, 257
pancreatic cancer, nonsteroidal anti-inflammatory drugs and, 1168
Assays
cell-based assays for identification of novel double-strand break-inducing agents, 88
3D reconstituted basement membrane assay, 1494[cell lines], 1894 (*erratum*)
ATM, breast cancer, dominant negative mutations, 205, 951 (correspondence)
Atomic bomb radiation, nervous system and pituitary gland tumors, 1555
Atypical squamous cells of undetermined significance (ASCUS), HPV testing, 102
Autocrine regulatory pathway, squamous cell carcinoma of the head and neck, gastrin-releasing peptide receptor (GSPR), 375

Barrett's esophagus, COX-2 and, 406 (editorial), 422 [cell cultures]
Behavioral Risk Factor Surveillance System, NHIS and, 1837
Beliefs and attitudes, racial/ethnic disparities, 353
Bias, all-cause mortality in randomized trials of cancer screening, 156 (editorial), 167, 861 (correspondence)
Biologic factors, racial/ethnic disparities, 353
Biologic samples, banking, Eastern Cooperative Oncology Group, 769
Biomarkers
breast cancer, biomarkers uPA and PAI-1, 116
colon cancer, osteopontin, 513
large B-cell lymphoma, MGMT promoter hypermethylation, 6 (editorial), 26
lung cancer, smoking and harm reduction, 1435
microvessel density, 883
renal cancer, VHL tumor suppressor gene, 1569
Biophosphonates, prostate cancer, 1422 (editorial), 1458
Bladder cancer
allelic imbalances, 216
arsenic-related chromosomal alterations and, 1688
smoking, and gender difference, 308 (correspondence)
STK15, and, 1320
Body surface area, dosage and, B (editorial), 1883
Bone matrix turnover, prostate cancer bone metastasis, 4 (editorial), 17
Brain metabolism, tamoxifen and estrogen, elderly women, 547 (editorial), 592, 1336 (correspondence)
BRCA
breast cancer, risk, 1344 (editorial), 1358, 1365
breast cancer, oral contraceptives in mutation carriers, 1773

breast cancer, risk and penetrance estimates, 1185 (editorial), 1221
multiple myeloma, family study and review of the literature, 461 (correspondence)
mutation, prediction by risk counselors and computer model DRCAPRO, 844, 1582 (correspondence)
ovarian cancer, 61, 960 (editorial), 990, 1344 (editorial), 1358, 1365, 1396, 1506 (correspondence)
prediction of mutation by risk counselors and computer model DRCAPRO, 844, 1582 (correspondence)
Breast
3D reconstituted basement membrane assay, 1494 [cell lines], 1894 (*erratum*)
leptin, normal and malignant growth factor, 1704 [cell lines]
self-examination, 1420 (editorial), 1445
Breast cancer
adjuvant chemotherapy, postmenopausal lymph node-negative, 1041 (editorial), 1054, 1339 (*erratum*)
adjuvant multi-agent chemotherapy and tamoxifen, trends, 1626
adrenomedullin, 1226 [cell lines] risk factors at young ages in twins, 1238
antiperspirant use and, 1578
ATM mutations, dominant negative, 205, 951 (correspondence)
biomarkers uPA and PAI-1, 116
BRCA1, 1344 (editorial), 1358, 1365, 1504 (correspondence)
BRCA1/2, penetrance estimates, 1185 (editorial), 1221
BRCA1/2, prediction of mutation, 844, 1582 (correspondence)
breast self-examination and, 1420 (editorial), 1445
care quality, and cancer registry data, 835
dairy products, calcium, and vitamin D, 1301
DCIS, mammography, 1546
1,1-dichloro-2,2-bis-(*p*-chlorophenyl)ethylene and polychlorinated biphenyls, 1337 (correspondence)
EBV and, 1832 (commentary)
endogenous sex hormones in menopause, and risk, 606
estrogen deprivation and apoptosis, 1173 [cell lines] (correspondence)
HER2, 788 (editorial), 852, 1581 (correspondence), 1807 (correspondence)
HER-2/neu [rats], 1808 (correspondence)
HercepTest™ local versus central testing, 855
loss of heterozygosity and risk, 858
mammography, diagnostic, 1151
mastectomy by menstrual cycle phase, 641 (editorial), 662, 1719 (correspondence)
men, contralateral cancer risk, 1330
men, second primary cancer, 1330, 1892 (correspondence)
mortality, U.S., 943
night shift work, light at night and, 530 (correspondence)
oophorectomy, 641 (editorial), 662, 1433, 1719 (correspondence)
oral contraceptives in BRCA1/2 mutation carriers, 1773
proton magnetic resonance spectroscopy, 1197
quality of life in long-term survivors, 39, 463 (*erratum*)
race and socioeconomic status, treatment and survival, 471 (editorial), 490, 1254 (correspondence)
radiotherapy, after lumpectomy, node-negative, 1114 (editorial), 1143
raloxifene after tamoxifen, 242 (editorial), 274 [mice]
risk perception and prophylactic mastectomy, 1564
screening, 1837
sulfotransferase 1A1 genotype, tamoxifen, and survival, 1635
tamoxifen for prevention, 1504 (correspondence)
treatment, racial/ethnic disparities, 336
Breast-conserving surgery, racial/ethnic disparities, 339
Bronchial dysplasia, lung cancer, anethole dithiolethione in smokers, 1001

CA 125, cancer screening and diagnostics, 1697
Calcium
breast cancer, and, 1301
colon cancer, and calcium intake, 437
Cancer registry, breast cancer care quality, and registry data, 835
Cancer Surveillance Series, Kaposi's sarcoma, 1204 non-Hodgkin's lymphoma, 1204
Capsaicin, tumor cells and, 1263 (editorial), 1281 [cell lines]
Carbohydrates, tumor growth and metastasis and, 1854 [mice and cell lines]
Carboplatin plus paclitaxel, non-small-cell lung cancer, 291, 1172 (correspondence)
CD13/aminopeptidase N, leukemia, interleukin 8, and apoptosis mediated by endothelial cells, 1020 [cell lines]
CD36 receptor, angiogenesis, GcMAF, 1311 [cell lines]
CD40, urothelial cells, 1381 [cell lines]
CDKN2A mutations, melanoma, geographic variation, 872 (editorial), 894
Cell-based screening, drug discovery, 78 (editorial)
Cells, leptin, growth factor in normal and malignant breast cells, 1704 [cell lines]
Cell toxics, cell-based assays for identification of novel double-strand break-inducing agents, 88
Cervical cancer
cost-effectiveness of screening, developing countries, 1469
HPV, and, 1249, 1406, 1592 (editorial), 1604
HSV-2, and, 1592 (editorial), 1604
screening, Chinese-North Americans, 670
screening, cost-effectiveness, 193
treatment, racial/ethnic disparities, 340
Chemoprevention, 253
lung cancer, anethole dithiolethione in smokers, 1001
pancreatic cancer, nonsteroidal anti-inflammatory drugs and, 1168
Chemotherapy
hiccups and, 772 (correspondence), 1175 (correspondence)
Hodgkin's disease followed by lung cancer, 182
lung cancer, anemia and darbepoetin alfa, 1184 (editorial), 1211
ovarian cancer, noninvasive imaging, 706 (editorial), 741 [mice]
oral, 652, 1652 (correspondence)
pancreatic cancer, prb expression, and chemotherapy-induced apoptosis, 129
screening, 1837
Children and adolescents, adherence, 657
Chili peppers, tumor cells and capsaicin, 1263 (editorial), 1281 [cell lines]
China
lung cancer, household stove improvement, 826
lung cancer, insulin-like growth factor I, IGF-binding protein 3, in men, 749
nasopharyngeal cancer, HLA I and II alleles, Taiwan, 1780
Chinese-Americans
cervical cancer screening, 670
metabolism, and nicotine intake from cigarette smoking, 108
Chinese-Canadians, cervical cancer screening, 670
Chives, prostate cancer and, 1648
Cigarette smoking. *See* Smoking
Circadian rhythm, tumor progression, 690 [mice]
Cisplatin-based therapy, non-small-cell lung cancer, elderly patients, 173, 1029 (correspondence)
Cisplatin plus vinorelbine, non-small cell lung cancer, 291, 1172 (correspondence)
Citrus pectin, tumor growth and metastasis and, 1854 [mice and cell lines]
Clinical staging, racial/ethnic disparities, 353
Clinical trials
all-cause mortality in randomized trials of cancer screening, 156 (editorial), 167, 861 (correspondence)

cervical cancer screening, Chinese-North Americans, 670
colorectal cancer, NSAIDs, 259
colorectal cancer, sigmoidoscopy, SCORE, 1763
ethics, 1821 (editorial), 1847
lung cancer, anethole dithiolethione in smokers, 1001
lung cancer, darbepoetin alfa for chemotherapy-associated anemia, 1184 (editorial), 1211
lung cancer, non-small-cell, Eastern Cooperative Oncology Group 5592, cisplatin-based therapy for elderly patients, 173, 1029 (correspondence)
prostate cancer, metastatic, zoledronic acid, 1422 (editorial), 1458
views of American oncologists, 1847
Colon cancer
adjuvant chemotherapy, African-Americans and Caucasians, 1160
calcium intake and, 437
osteopontin, 513
Colonoscopy, colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)
Colorectal cancer
age and second primary cancer, 529 (correspondence)
insulin, insulin-like growth factor-1 (IGF-1), IFG binding proteins, and, 972
metastatic, glutathione *S*-transferase P1, T1, and M1 genetic polymorphism and survival, 936
NSAIDs, 259
screening, 1837
screening for persons at average risk, 1126, 1507 (*erratum*)
sigmoidoscopy, Italian clinical trial, SCORE, 1763
T1663A GH1 polymorphism, 454
treatment, racial/ethnic disparities, 344
U.S. cancer mortality among men, 1950–1998, 916
wheat bran fiber intake, 1620
Colposcopy triage, atypical squamous cells of undetermined significance (ASCUS), and HPV testing, 102
Computers, BRCA1/2, prediction of mutation by risk counselors and computer model DRCAPRO, 844, 1582 (correspondence)
Conditioned nausea, psychological therapies, 577, 1810 (correspondence)
Conditioned vomiting, psychological therapies, 578, 1810 (correspondence)
Consent, banking biologic samples, Eastern Cooperative Oncology Group, 769
Cooperative Research and Development Agreement (CRADA), 3 (editorial)
Coping or control skills, psychological therapies, 571, 1810 (correspondence)
Cost-effectiveness, cervical cancer screening, developing countries, 1469
Cyclooxygenase (COX)-2
Barrett's esophagus and, 406 (editorial), 422 [cell cultures]
prostate cancer, apoptosis, 545 (editorial), 585
prostate cancer, prevention, 1732 (editorial), 1745 [cell lines]
Cyclophosphamide, large B-cell lymphoma, and MGMT promoter hypermethylation, 6 (editorial), 26
CYP3A4, prostate cancer, modification of presentation of tumors by a genetic variant in CYP3A4, 630 (correspondence)

Dairy products, breast cancer, and, 1301
Darbepoetin alfa, lung cancer, 1184 (editorial), 1211
DCs, immunotherapy, 808, 810
Depression, psychological therapies, 563, 1810 (correspondence)
Developing countries
cervical cancer screening, cost-effectiveness, 1469
lung cancer, household stove improvement, China, 826
Diagnostics
breast cancer, mammography, 1151, 1546
genito-urinary cancer, minichromosome maintenance 5 protein in urine sediment, 1071
prostate cancer, serum proteomic patterns and, 1576
proton magnetic resonance spectroscopy, breast lesions, 1197
screening, CA 125 and plasma DNA, 1697
1,1-Dichloro-2,2-bis-(*p*-chlorophenyl) ethylene, breast cancer, 1337 (correspondence)
Diet
breast cancer, dairy products, calcium, and vitamin D, 1301
carbohydrates, tumor growth and metastasis and, 1854 [mice and cell lines]
colon cancer, and calcium intake, 437
colorectal cancer and wheat bran fiber intake, 1620
pancreatic cancer, sugar and glycemic load, 1293
prostate cancer, tomato products and lycopene, 391
Dietary supplements, prostate cancer, PC-SPES herbal composition, 1261 (editorial), 1275
Diphtheria toxin fusion protein DTAT, glioblastoma, 597
Diurnal sleep disruption, breast cancer and, 530 (correspondence)
DNA
cancer screening and diagnostics, plasma levels, 1697
liver cancer, methylation, geographic variation, 755
DNA repair
cutaneous malignant melanoma, 94, 772 (correspondence)
non-small-cell lung cancer, determinant of survival, 1091
Docosahexaenoic acid (DHA), body surface area, and dosage, 1822 (editorial), 1883
Domestic adjustment, psychological therapies, 572, 1810 (correspondence)
Dosage, body surface area and, 1822 (editorial), 1883
DRCAPRO computer model, BRCA1/2, prediction of mutation, and 844
Drug discovery, cell-based screening and, 78 (editorial)
Drug resistance, MCF-7 cells, 1652 [cell lines] (correspondence)
DTAT, glioblastoma, 597
Dysplastic nevi, cutaneous malignant melanoma, 94, 772 (correspondence)

Eastern Cooperative Oncology Group, banking biologic samples, 769
Economics, non-small-cell lung cancer, vinorelbine plus cisplatin versus placlitaxel plus carboplatin, 291, 1172 (correspondence)
Elderly patients, non-small-cell lung cancer, cisplatin-based therapy, 173, 1029 (correspondence)
Endocrines, breast cancer, postmenopausal lymph node-negative, adjuvant chemotherapy, 1041 (editorial), 1054, 1339 (*erratum*)
Endometrial cancer, raloxifene after tamoxifen, 242 (editorial), 274 [mice]
Endoscopic screening, colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)
Eniluracil, body surface area, and dosage, 1822 (editorial), 1883
Epidemiology, AIDS-related non-Hodgkin's lymphoma, U.S. and East Africa, 718
Epithelial cells, prostate cancer, arsenic-induced malignant transformation, 1888 [cell lines]
Epstein-Barr virus (EBV)
cancer and, 1832 (commentary)
Hodgkin's lymphoma, EBV-related infectious mononucleosis in relatives, 678
malignant and nonmalignant diseases, BZLF1 polymorphisms, 1733 (editorial), 1757
nasopharyngeal cancer, HLA I and II alleles, Taiwan, 1780

nasopharyngeal cancer, prognosis, 1594 (editorial), 1614
ErbB1/2, lung cancer, FK228 and, 504 [cell lines]
ERK2 signaling pathways, prostate cancer, cyclooxygenase-2 inhibitors, prevention, 1732 (editorial), 1745 [cell lines]
Errata
"Colorectal Cancer Screening for Persons at Average Risk" by Anderson et al. [J Natl Cancer Inst 2002; 94:1126–33 (Issue 15)], 1507
"Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial" by the International Breast Cancer Study Group [J Natl Cancer Inst 2002;94:1054–1065 (Issue 14)], 1339
"Human Papillomavirus Type 16 Variants and Risk of Cervical Cancer" by Hildesheim et al. [J Natl Cancer Inst 2001;93:315–8 (Issue 4)], 866
"Inhibition of Human Squamous Cell Carcinoma Growth *In Vivo* by Epidermal Growth Factor Receptor Antisense RNA Transcribed From the U6 Promoter" by He et al. [J Natl Cancer Inst 1998;90:1080–7 (Issue 14)], 633
"$p16^{Ink4a}$ in Melanocyte Senescence and Differentiation" by Sviderskaya et al. [J Natl Cancer Inst 2002;94:446–54 (Issue 6)], 866
"Phenotypic Reversion or Death of Cancer Cells by Altering Signaling Pathways in Three-Dimensional Contexts" by Wang et al. [J Natl Cancer Inst 2002;94:1494–1503 (Issue 19)], 1894
"Quality of Life in Long-Term Disease Free Survivors of Breast Cancer: A Follow-up Study" by Ganz et al. [J Natl Cancer Inst 2002;94:39–49 (Issue 1)], 463
"Side Effects of Chemotherapy and combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer" by Partridge et al. [J Natl Cancer Inst 2001;30:135–42], 966
Esophageal cancer, COX-2, Barrett's esophagus and, 406 (editorial)
17β-Estradiol
breast cancer and apoptosis, 1173 [cell lines] (correspondence)
ovarian cancer and IL-6/STAT3 activation, 617 [cell lines], 1255 (correspondence)
Estrogen
brain metabolism, elderly women, 547 (editorial), 592, 1336 (correspondence)
breast cancer and apoptosis, 1173 [cell lines] (correspondence)
ovarian cancer, progestin and estrogen potency in oral contraceptives and risk, 32
Estrogen receptors, prostate cancer, methylation and inactivation, 384 [cell lines]
Estrone, ovarian cancer and IL-6/STAT3 activation, 617 [cell lines] , 1255 (correspondence)
Ethics, 1821 (editorial), 1847
Ethnicity. *See* Race and ethnicity
Ewing's sarcoma, imatinib, 1660 (editorial), 1673 [mice]

5-Fluorouracil, body surface area, and dosage, 1822 (editorial), 1883
FAP, NSAIDs, 256
Fatigue, psychological therapies, 577, 1810 (correspondence)
Fecal multi-targeted DNA-based assay panel test, colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)
Fecal occult blood test, colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)
FISH assay, local versus central testing, 855
Follicle-stimulating hormone, ovarian cancer and IL-6/STAT3 activation, 617 [cell lines], 1255 (correspondence)
Functional ability, psychological therapies, 570, 1810 (correspondence)

Garlic, prostate cancer and, 1648
Gastrin-releasing peptide receptor (GSPR), squamous cell carcinoma of the head and neck, 375
Gender difference, lung cancer and cancer, and smoking, 308 (correspondence)
Genes and genetics. *See also* Mutations.
bladder cancer, allelic imbalances, 216
bladder cancer, STK15 and, 1320
breast cancer, dominant negative ATM mutations, 205, 951 (correspondence)
breast cancer, HER2, 1807 (correspondence)
breast cancer, HER-2/neu [rats], 1808 (correspondence)
cancer therapy, Ras signaling, 1031 (correspondence)
colorectal cancer, metastatic, glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival, 936
genetic testing, 1837
liver cancer, DNA methylation of CpG island, geographic variation, 755
lung cancer, non-small cell, β-tubulin gene TUBB, 774 (correspondence)
lymphoma, diffuse large B-cell, O^6-methylguanine DNA methyltransferase (MGMT) and, 6 (editorial), 26
malignant and nonmalignant diseases, BZLF1 polymorphisms, Epstein-Barr virus, 1733 (editorial), 1757
melanocyte senescence and differentiation, Ink4a-Arf, 446 [mice], 866 (*erratum*)
melanoma, CDKN2A mutations, geographic variation, 872 (editorial), 894
neuroblastoma, apoptosis, Ras, and caspace-independent cell death, 319 (editorial), 358
ovarian cancer, BRCA1/2 mutations, 960 (editorial), 990, 1506 (correspondence)
pancreatic cancer, GSTT1 polymorphism, and smoking, 297
pancreatic cancer, pRB, and chemotherapy-induced apoptosis, 129
prostate cancer, methylation and inactivation of estrogen, progesterone, and androgen receptors, 384 [cell lines]
prostate cancer, modification of presentation of tumors by a genetic variant in CYP3A4, 630 (correspondence)
prostate cancer, TIG1, 469 (editorial), 482 [cell lines]
ras, 1516 (editorial), 1527
renal cancer, VHL tumor suppressor gene, 1569
survivin, 522 [cell lines]
tumorigenesis, K1, human herpesvirus-8, and aberrant signaling, 926 [mice]
Wilms tumor, insulin-like growth factor-II gene, subtypes, 1809 (correspondence)
see also BRCA
Gene therapy
ovarian cancer, adenovirus-based, noninvasive imaging, 706 (editorial), 741 [mice]
head and neck cancer, tumor growth, interleukin 12 electro-gene therapy, 762 [mice]
Genito-urinary cancer, diagnosis, minichromosome maintenance 5 protein in urine sediment, 1071
Genotypes
lung cancer, p53 genotypes and haplotypes associated with, 681
stomach cancer, *Helicobacter pylori,* and interleukin 1, 1662 (editorial), 1680
Geographic variation
liver cancer, DNA methylation of CpG island, 755
melanoma, CDKN2A mutations, 872 (editorial), 894
Glioblastoma, DTAT, 597
Glioma, γ-radiation sensitivity and risk, 949 (correspondence)
Glucose transporter 1, human cancers, coexpression with MMP-2, 1080 [cell lines]

Glutathione S-transferase, metastatic colorectal cancer, P1, T1, and M1 genetic polymorphism and survival, 936
Glycemic load, pancreatic cancer, sugar and, 1293
GSTT1, pancreatic cancer, smoking and polymorphism, 297

Haplotypes, lung cancer, p53 genotypes and haplotypes associated with, 681
HDM2 protein, melanoma, prognosis, 1803
Head and neck cancer
squamous cell carcinoma, gastrin-releasing peptide receptor-mediated autocrine growth, 375
tumor growth, interleukin 12 electro-gene therapy, 762 [mice]
Health care
breast cancer, and cancer registry data, 835
racial/ethnic disparities, 334
Heat shock proteins, vaccination with, 811
Helicobacter pylori
pancreatic cancer risk, 632 (correspondence)
stomach cancer, and interleukin 1 genotyping, 1662 (editorial), 1680
Hematopoietic cancers, EBV-related infectious mononucleosis in relatives, 678
HER2, breast cancer, 788 (editorial), 852, 1581 (correspondence), 1807 (correspondence)
HER-2/neu [rats], 1808 (correspondence)
Herbs, PC-SPES, prostate cancer, 1641 [mice]
HercepTest™ local versus central testing, 855
Heredity, ovarian cancer, BRCA1/2 mutations, 960 (editorial), 990, 1506 (correspondence)
Herpes simplex virus-2 (HSV-2), cervical cancer, HPV, and, 1592 (editorial), 1604
Hiccups, chemotherapy adverse reaction, 772 (correspondence), 1175 (correspondence)
Histone deacetylases, lung cancer, FK228 and, 504 [cell lines]
HLA I and II alleles, nasopharyngeal cancer, Taiwan, 1780
Hodgkin's disease
EBV-related infectious mononucleosis in relatives, 678
lung cancer following chemotherapy and radiotherapy, 182
Hormone replacement therapy
brain metabolism, elderly women, 547 (editorial), 592, 1336 (correspondence)
ovarian cancer and, 497
Hostility, psychological therapies, 569, 1810 (correspondence)
Human herpesvirus 8
Kaposi's sarcoma, elderly males, 1333
K1 gene, tumorigenesis, and aberrant signaling, 926 [mice]
Human papilloma virus
atypical squamous cells of undetermined significance (ASCUS), 102
cancer and, 1832 (commentary)
cervical cancer, 1249, 1406, 1592 (editorial), 1604
Human telomerase reverse transcriptase (hTERT), *N*-(4-hydroxyphenyl)retinamide, and hTERT expression in bronchial epithelium of cigarette smokers, 949 (correspondence)
HuMV833, solid tumors, molecular imaging and biological evaluation, 1484
***N*-(4-Hydroxy-phenyl)retinamide,** hTERT expression in bronchial epithelium of cigarette smokers, 949 (correspondence)
Hypermethylation, DNA repair gene, 6 (editorial), 26

IFG binding proteins, colorectal cancer, and, 972
IGF binding protein-3, prostate cancer, 1099, 1893 (correspondence)
Imaging, noninvasive, ovarian cancer, noninvasive imaging, 706 (editorial), 741 [mice]
Imatinib, Ewing's sarcoma, 1660 (editorial), 1673 [mice]
Immune outcomes, psychological therapies, 578, 1810 (correspondence)
Immunotherapy, peptide-based vaccines, 805
Incidence
prostate cancer, PSA screening, 958 (editorial), 981
rates, reporting delay and reporting error and, 1537
Infectious mononucleosis, EBV-related, hematopoietic and lymphatic cancers in relatives, 678
Inflammation, radiation-induced pulmonary fibrosis and respiratory insufficiency, 704 (editorial), 733 [mice]
Information for authors, 73, 539, 1035, 1511
Insulin
colorectal cancer, and, 972
pancreatic cancer, sugar and glycemic load, and resistance, 1293
Insulin-like growth factor-1 (IGF-1)
colorectal cancer, and, 972
lung cancer, men in China, 749
prostate cancer, 1099, 1893
Insulin-like growth factor-binding protein 3, lung cancer, men in China, 749
Insulin-like growth factor-II gene, Wilms tumor, subtypes, 1809 (correspondence)
Interferon β, ovarian cancer, tumor growth, 1010 [mice]
Interleukin 1 genotyping, stomach cancer, and *Helicobacter pylori,* 1662 (editorial), 1680
Interleukin 6, ovarian cancer and, 617 [cell lines], 1255 (correspondence)
Interleukin 8, leukemia, CD13/aminopeptidase N, and apoptosis mediated by endothelial cells, 1020 [cell lines]
Interleukin 12, head and neck cancer, tumor growth, interleukin 12 electro-gene therapy, 762 [mice]
Interpersonal relationships, psychological therapies, 572, 1810 (correspondence)
Intestinal cancer, NSAIDs, 255 [rodents]
Intracellular adhesion molecule 1 (ICAM-1), radiation-induced pulmonary fibrosis and respiratory insufficiency, 704 (editorial), 733 [mice]
Irinotecan, St. John's wort and metabolism, 1187 (editorial), 1247

JNCI Cancer Spectrum, 3 (editorial)
Journal of the National Cancer Institute, inspiration of Janus, 3 (editorial)

K1, human herpesvirus-8, tumorigenesis, and aberrant signaling, 926 [mice]
Kaposi's sarcoma
human herpesvirus 8, elderly males, 1333
incidence, 1204
risk factors, 1712

Leeks, prostate cancer and, 1648
Leptin, breast, normal and malignant growth factor, 1704 [cell lines]
Leukemia, interleukin 8, CD13/aminopeptidase N, and apoptosis mediated by endothelial cells, 1020 [cell lines]
Light, breast cancer and, 530 (correspondence)
Liver cancer, DNA methylation of CpG island, geographic variation, 755
Loss of heterozygosity (LOH)
breast cancer risk, 858
ovarian cancer, BRCA1 dysfunction in, 61
Lung cancer
alcohol consumption and, 1877
darbepoetin alfa, 1184 (editorial), 1211
following chemotherapy and radiotherapy for Hodgkin's disease, 182
household stove improvement, China, 826
insulin-like growth factor I, IGF-binding protein 3, men in China, 749

p53 genotypes and haplotypes associated with, 681
small-cell, treatment, racial/ethnic disparities, 344
smoking, and gender difference, 308 (correspondence)
U.S. cancer mortality among men, 1950–1998, 916
Lung cancer, non-small-cell
African-American versus non-African-American, 284
cisplatin-based therapy for elderly patients, 173, 1029 (correspondence)
DNA repair as a determinant of survival, 1091
genetic analysis, β-tubulin gene TUBB, 774 (correspondence)
p3, ErbB1, ErbB2, and Raf-1, FK228 and, 504 [cell lines]
treatment, racial/ethnic disparities, 344
vinorelbine plus cisplatin versus placlitaxel plus carboplatin, economic analysis, 291, 1172 (correspondence)
Lungs, radiation-induced pulmonary fibrosis and respiratory insufficiency, 704 (editorial), 733 [mice]
Luteinizing hormone, ovarian cancer and IL-6/STAT3 activation, 617 [cell lines], 1255 (correspondence)
Lycopene, prostate cancer, 391
Lymph node metastasis, VEGFR-3 and, 785 (editorial), 819 [cell line]
Lymphatic cancers, EBV-related infectious mononucleosis in relatives, 678
Lymphatic vessels, intratumoral, metastasis and, 417 (commentary)
Lymphoma, large B-cell, MGMT promoter hypermethylation, 6 (editorial), 26

Macrophages, tumoricidal, GcMAF, 1311 [cell lines]
Malignant transformation, CD40, urothelial cells, 1381 [cell lines]
Mammography, breast cancer, 1151, 1546
false-positives, 1346 (editorial), 1373
volume and accuracy, 321 (editorial), 369
Marital relationships, psychological therapies, 572, 1810 (correspondence)
Mastectomy
breast cancer, by menstrual cycle phase, 641 (editorial), 662, 1719 (correspondence)
prophylactic, breast cancer risk perception and, 1564
risk-reduction, 143 (correspondence), 307 (correspondence)
Matrix metalloproteinase-2, human cancers, coexpression with glucose transporter 1, 1080 [cell lines]
Matrix metalloproteinases (MMPs), prostate cancer in bone and, 4 (editorial), 17
MCF-7, 1652 [cell lines] (correspondence)
Medicare, NHIS and, 1837
Medulloblastoma, JCV polyomavirus and, 240 (editorial), 267
Melanoma
CDKN2A mutations, geographic variation, 872 (editorial), 894
HDM2 protein, prognosis, 1803
Menopause, breast cancer
dairy products, calcium, and vitamin D, 1301
endogenous sex hormones and risk, 606
postmenopausal lymph node-negative, adjuvant chemotherapy, 1041 (editorial), 1054, 1339 (*erratum*)
Menstrual cycle phase, breast cancer, mastectomy and oophorectomy and, 641 (editorial), 662, 1719 (correspondence)
Mesothelioma, SV40 and cancer, 229 (correspondence)
Metabolism, nicotine intake from cigarette smoking, Chinese-Americans, 108
Metalloproteinase-9, ovarian cancer, stromal therapy, 1113 (editorial), 1134 [mice]
Metastasis
carbohydrates and, 1854 [mice and cell lines]
colorectal cancer, glutathione *S*-transferase P1, T1, and M1 genetic polymorphism and survival, 936
intratumoral lymphatic vessels and, 417 (commentary)
lymph node, VEGFR-3 and, 785 (editorial), 819 [cell line]
prostate cancer in bone, and MMPs, 4 (editorial), 17
prostate cancer, zoledronic acid, 1422 (editorial), 1458
***O*^{6}-Methylguanine DNA methyltransferase (MGMT),** 6 (editorial), 26
Microvessel density, antiangiogenic therapy, 883
Mitotic kinase, bladder cancer, and STK15, 1320
Mortality
all cancers among men, socioeconomic status, U.S., 1950–1998, 904
breast cancer, U.S., 943
colorectal cancer, U.S. cancer mortality among men, 1950–1998, 916
disease-specific versus all-cause in randomized trials, 156 (editorial), 167, 861 (correspondence)
lung cancer, U.S. cancer mortality among men, 1950–1998, 916
probability, 799, 1584 (correspondence)
racial/ethnic disparities, 334
treatment-related deaths of cancer patients, 1044 (editorial), 1066
Multiple myeloma, family study and review of the literature, 461 (correspondence)
Mutations. *See also* Genes and genetics
ATM, breast cancer, 205, 951 (correspondence)
cell-based assays for identification of novel double-strand break-inducing agents, 88
radiation-induced pulmonary fibrosis and respiratory insufficiency, 704 (editorial), 733 [mice]
ras, 1516 (editorial), 1527

Nasopharyngeal cancer
EBV and prognosis, 1594 (editorial), 1614
HLA I and II alleles, Taiwan, 1780
National Health Interview Survey (NHIS), 1987–1998, 1837
National Surgical Adjuvant Breast and Bowel Project, HER2 assays, 788 (editorial), 852
Natural killer (NK) cells, Sindbis viral vectors, anticancer activity, 1790 [mice]
Nausea, psychological therapies, 572, 577, 1810 (correspondence)
Nerve block, cervical phrenic, hiccups in cancer patients, 1175 (correspondence)
Nervous system tumors, atomic bomb radiation, 1555
Neuroblastoma, ras expression and caspase-independent cell death, 319 (editorial), 358
Nicotine, intake from cigarette smoking, and metabolism, Chinese-Americans, 108
Night shift work, breast cancer, 530 (correspondence)
Nitrosylcobalamin, ovarian cancer, tumor growth, 1010 [mice]
Non-Hodgkin's lymphoma
AIDS-related, U.S. and East Africa, 718
incidence, 1204
Nonsteroidal anti-inflammatory drugs (NSAIDs)
anticancer agents, 252
pancreatic cancer and, 1168

Onions, prostate cancer and, 1648
Oophorectomy
breast cancer, 1433
breast cancer, by menstrual cycle phase, 641 (editorial), 662, 1719 (correspondence)
Oral antineoplastic agents, adherence to therapy, 652, 1652 (correspondence)
Oral contraceptives
breast cancer, BRCA1/2 mutation carriers, 1773
ovarian cancer, progestin and estrogen potency in oral contraceptives and risk, 32

Oropharyngeal cancer, HPV, EBV and, 1832 (commentary)
Osteopontin, colon cancer, 513
Ovarian cancer
adenovirus-based gene therapy, and noninvasive imaging, 706 (editorial), 741 [mice]
BRCA1, 61, 960 (editorial), 990, 1344 (editorial), 1358, 1365, 1506 (correspondence)
BRCA1/2 inactivation, 1396
HRT and, 497
IL-6 and, 617 [cell lines], 1255 (correspondence)
progestin and estrogen potency in oral contraceptives and risk, 32
stromal therapy, 1113 (editorial), 1134 [mice]
tumor growth, nitrosylcobalamin, interferon β, and transcobalamin II-receptor, 1010 [mice]
Ovary, progestin-induced apoptosis, transforming growth factor-ß and, 50 [macaque]

$p16^{Ink4a}$, melanocyte senescence and differentiation, 446 [mice], 866 (*erratum*)
p53, lung cancer
FK228 and, 504 [cell lines]
genotypes and haplotypes associated with, 681
Paclitaxel
prostate cancer, 1641 [mice]
body surface area, and dosage, 1822 (editorial), 1883
Paclitaxel plus carboplatin, non-small-cell lung cancer, 291, 1172 (correspondence)
Pain, psychological therapies, 572, 1810 (correspondence)
Pancreatic cancer
Helicobacter pylori, 632 (correspondence)
nonsteroidal anti-inflammatory drugs and, 1168
pRB expression, chemotherapy-induced apoptosis, 129
smoking and polymorphism in GSTT1, 297
sugar and glycemic load, 1293
PC-SPES, prostate cancer, 1261 (editorial), 1275, 1641 [mice]
Penetrance estimates, breast cancer, BRCA1/2 and risk, 1185 (editorial), 1221
Peptides, modified and optimized, 806
PERFORMS 2 test, mammography volume and accuracy, 321 (editorial), 369
Phenotypic reversion, 3D reconstituted basement membrane assay, 1494 [cell lines], 1894 (*erratum*)
Physical symptoms, psychological therapies, 577, 1810 (correspondence)
Pituitary gland tumors, atomic bomb radiation, 1555
Placlitaxol. *See* Taxol
Pollution, bladder cancer, arsenic-related chromosomal alterations and, 1688
Polo-like kinase-1, RNA, apoptosis, and spindle formation, 1863 [cell lines]
Polychlorinated biphenyls, breast cancer, 1337 (correspondence)
Polyomavirus JCV, medulloblastoma and, 240 (editorial), 267
Prevention, prostate cancer, cyclooxygenase-2 inhibitors, 1732 (editorial), 1745 [cell lines]
Progesterone receptors, prostate cancer, methylation and inactivation, 384 [cell lines]
Progestin
ovarian cancer, HRT and, 497
ovarian cancer, progestin and estrogen potency in oral contraceptives and risk, 32
ovary, progestin-induced apoptosis, transforming growth factor-ß and, 50 [macaque]
Prognosis
breast cancer, biomarkers uPA and PAI-1, 116
Epstein-Barr virus, BZLF1 polymorphisms, malignant and nonmalignant diseases, 1733 (editorial), 1757
melanoma, HDM2 protein, 1803
microvessel density, 883
nasopharyngeal cancer and EBV, 1594 (editorial), 1614
renal cancer, VHL tumor suppressor gene, 1569
Prostate cancer
allium vegetables and, 1648
androgen deprivation therapy, and quality of life, 407 (editorial), 430
arsenic-induced malignant transformation, 1888 [cell lines]
bone metastasis, and MMPs, 4 (editorial), 17
COX-2, apoptosis, 545 (editorial), 585
cyclooxygenase-2 inhibitors, prevention, 1732 (editorial), 1745 [cell lines]
CYP3A4, tumors modification by a genetic variant, 630 (correspondence)
insulin-like growth factor-I and IGF binding protein, and, 1099, 1893 (correspondence)
metastatic, zoledronic acid, 1422 (editorial), 1458
methylation and inactivation of estrogen, progesterone, and androgen receptors, 384 [cell lines]
PC-SPES, 1261 (editorial), 1275, 1641 [mice]
population-based screening, 227 (correspondence)
PSA screening, incidence trends, 958 (editorial), 981
screening, 1837
serum proteomic patterns and, 1576
TIG1 and, 469 (editorial), 482 [cell lines]
tomato products, lycopene, and risk, 391
treatment, racial/ethnic disparities, 345
Prostate-specific antigen screening, prostate cancer, incidence trends, 958 (editorial), 981
Proteins, genito-urinary cancer, diagnosis, minichromosome maintenance 5 protein in urine sediment, 1071
Proteomic patterns, serum, prostate cancer and, 1576
Proton magnetic resonance spectroscopy (^{3}H MRS), breast lesions, 1197
Psychological therapies, review, 558, 1810 (correspondence)

Quality of life
breast cancer, long-term survivors, 39, 463 (*erratum*)
prostate cancer, androgen deprivation therapy, 407 (editorial), 430
psychological therapies, 570, 1810 (correspondence)

Race and ethnicity
breast cancer treatment and survival, 471 (editorial), 490, 1254 (correspondence)
cancer mortality, 334
colon cancer, adjuvant chemotherapy, African-Americans and Caucasians, 1160
lung cancer, p53 genotypes and haplotypes associated with, 681
nasopharyngeal cancer, HLA I and II alleles, Taiwan, 1780
Radiation
glioma risk, γ-radiation, 949 (correspondence)
nervous system and pituitary gland tumors, atomic bomb radiation, 1555
pulmonary fibrosis and respiratory insufficiency, 704 (editorial), 733 [mice]
skin cancer risk, UV radiation, 224
Radiotherapy
breast cancer, scheduling after lumpectomy, node-negative, 1114 (editorial), 1143
Hodgkin's disease followed by lung cancer, 182
racial/ethnic disparities, adjuvant radiation therapy, 339
Raf-1, lung cancer, FK228 and, 504 [cell lines]

Raloxifene, breast and endometrial cancer, after tamoxifen, 242 (editorial), 274 [mice]
Ras
blocking oncogenic signaling for cancer therapy, 1031 (correspondence)
cancer and, 1516 (editorial), 1527
neuroblastoma, caspace-independent cell death, 319 (editorial), 358
Recurrence, colorectal cancer and wheat bran fiber intake, 1620
Renal cancer, VHL tumor suppressor gene, 1569
Reporting delay and reporting error, cancer incidence rates and trends, 1537
Research
ethics, 1821 (editorial), 1847
future, 1837
Retinoblastoma tumor-suppressor gene pRB, pancreatic cancer, and chemotherapy-induced apoptosis, 129
RGDTKSSTR, ovarian cancer, noninvasive imaging, 706 (editorial), 741 [mice]
Risk, charts to put cancer in context, 799, 1584 (correspondence)
RNA, polo-like kinase-1, apoptosis, and spindle formation, 1863 [cell lines]

Scallions, prostate cancer and, 1648
Screening
cervical cancer, cost-effectiveness, 193
cervical cancer, developing countries, cost-effectiveness, 1469
colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)
colorectal cancer, sigmoidoscopy, Italian clinical trial, SCORE, 1763
mortality in randomized trials, 156 (editorial), 167, 861 (correspondence)
NHIS, 1837
prostate cancer, population-based, 227 (correspondence)
prostate cancer, PSA, and incidence trends, 958 (editorial), 981
Second primary cancer, breast cancer in men, 1330, 1892 (correspondence)
Seppuku, neuroblastoma, 319 (editorial)
Sex hormones, endogenous, breast cancer risk in menopause, 606
Sexual relationships, psychological therapies, 572, 1810 (correspondence)
Sigmoidoscopy, colorectal cancer
flexible sigmoidoscopy, for persons at average risk, 1126, 1507 (*erratum*)
Italian clinical trial, SCORE, 1763
Signaling pathways, 3D reconstituted basement membrane assay, 1494 [cell lines], 1894 (*erratum*)
Simian virus 40
vaccines and cancer, 229 (correspondence)
cancer and, 1832 (commentary)
Sindbis virus, anticancer activity, 1790 [mice]
Single-nucleotide polymorphism (SNP) arrays, bladder cancer, scanning for allelic imbalances, 216
Skin cancer
basal cell and squamous cell, tanning devices and risk, 224
cutaneous malignant melanoma, DNA repair, dysplastic nevi, and sunlight, 94, 772 (correspondence)
Smoking
bladder cancer, gender difference, 308 (correspondence)
cervical cancer, HPV, and, 1406
harm reduction, and biomarkers, 1435
HPV and, 1832 (commentary)
Kaposi's sarcoma, risk factors, 1712
lung cancer, anethole dithiolethione and, 1001
lung cancer, gender difference, 308 (correspondence)
lung cancer, smoking and harm reduction, 1435
N-(4-hydroxy-phenyl)retinamide, and hTERT expression in bronchial epithelium of cigarette smokers, 949 (correspondence)
nicotine intake, and metabolism, Chinese-Americans, 108
pancreatic cancer and polymorphism in GSTT1, 297
risk charts, 801
Social relationships, psychological therapies, 572, 1810 (correspondence)
Socioeconomic status
all cancers among men, U.S. cancer mortality, 1950–1998, 904
breast cancer treatment and survival, 471 (editorial), 490, 1254 (correspondence)
colorectal cancer, U.S. cancer mortality among men, 1950–1998, 916
lung cancer, non-small-cell, African-American versus non-African-American, 284
lung cancer, U.S. cancer mortality among men, 1950–1998, 916
racial/ethnic disparities, 353
Solid tumors, HuMV833, molecular imaging and biological evaluation, 1484
Spindle formation, RNA and polo-like kinase-1 and, 1863 [cell lines]
Squamous cells
atypical, of undetermined significance (ASCUS), HPV testing, 102
low-grade, intraepithelial lesions (LSIL), HPV testing, 102
St. John's wort, irinotecan metabolism and, 1187 (editorial), 1247
STAT3-mediated interleukin 6, ovarian cancer and, 617 [cell lines], 1255 (correspondence)
Statistics, 799, 1584 (correspondence)
HNIS and, 1837
Stomach cancer, *Helicobacter pylori* and interleukin 1 genotyping, 1662 (editorial), 1680
Stress, psychological therapies, 570, 1810 (correspondence)
Stromal therapy, ovarian cancer, 1113 (editorial), 1134 [mice]
Sugar, pancreatic cancer, and glycemic load, 1293
Sulfotransferase 1A1 genotype, breast cancer, tamoxifen, and survival, 1635
Sunlight
cutaneous malignant melanoma, 94, 772 (correspondence)
exposure, 1837
Surgery, treatment-related deaths of cancer patients, 1044 (editorial), 1066
Survival
colorectal cancer, metastatic, glutathione *S*-transferase P1, T1, and M1 genetic polymorphism and survival, 936
non-small-cell lung cancer, DNA repair as a determinant of, 1091
psychological therapies, 578, 1810 (correspondence)
Survivin, gene expression, 522 [cell lines]
Sweden, ovarian cancer, and HRT, 497
Symptom management, lung cancer, darbepoetin alfa for chemotherapy-associated anemia, 1184 (editorial), 1211
Systemic adjuvant therapy, breast cancer, quality of life in long-term survivors, 39, 463 (*erratum*)

T1663A GH1, colorectal cancer, 454
Taiwan, nasopharyngeal cancer, HLA I and II alleles, 1780
Tamoxifen
brain metabolism, elderly women, 547 (editorial), 592, 1336 (correspondence)
breast cancer, 1041 (editorial), 1054, 1339 (*erratum*)
breast cancer, adjuvant multi-agent chemotherapy, trends, 1626
breast cancer, before raloxifene, 242 (editorial), 274 [mice]
breast cancer, mastectomy and oophorectomy by menstrual cycle phase, 641 (editorial), 662, 1719 (correspondence), 1722 (correspondence)
breast cancer, prevention, 1504 (correspondence) BRCA1-related, 1504 (correspondence)

breast cancer, sulfotransferase 1A1 genotype, and survival, 1635
endometrial cancer, before raloxifene, 242 (editorial), 274 [mice]
Tanning devices, skin cancer risk, 224
Target-based screening, drug discovery, 78 (editorial)
Taxol, breast cancer, HER2 assays, 788 (editorial), 852
Tazarotene-induced gene 1 (TIG1), prostate cancer and, 469 (editorial), 482 [cell lines]
Temozolomide, body surface area, and dosage, 1822 (editorial), 1883
Tobacco, smoking, harm reduction, and biomarkers, 1435
Tomato products, prostate cancer and, 391
Transcobalamin II-receptor, ovarian cancer, tumor growth, 1010 [mice]
Transforming growth factor-β, ovarian epithelium, progestin-induced apoptosis, 50 [macaque]
Trastuzumab. *See* Herceptin.
Treatment, blocking oncogenic Ras signaling for cancer therapy, 1031 (correspondence)
Trends, reporting delay and reporting error and, 1537
Troxacitabine, body surface area, and dosage, 1822 (editorial), 1883
β-Tubulin gene TUBB, non-small cell lung cancer, 774 (correspondence)
Tumor aggressiveness, racial/ethnic disparities, 353
Tumor-associated antigens (TAA), 805
Tumor cell proliferation, prostate cancer metastasis in bone and MMPs, 4 (editorial), 17
Tumor growth
carbohydrates, 1854 [mice and cell lines]
head and neck cancer, interleukin 12 electro-gene therapy, 762 [mice]
ovarian cancer, nitrosylcobalamin, interferon β, and transcobalamin II-receptor, 1010 [mice]
Tumorigenesis
human herpesvirus-8, K1 gene, and aberrant signaling, 926 [mice]
prostate cancer, TIG1 and, 469 (editorial), 482 [cell lines]
Tumor lymphangiogenesis, VEGFR-3 and, 785 (editorial), 819 [cell line]
Tumor peptides, T-cell responses, 807
Tumor progression
circadian rhythm, 690 [mice]
colon cancer, and osteopontin, 513
Twins, breast cancer, risk factors at young ages, 1238

United States
AIDS-related non-Hodgkin's lymphoma, U.S. and East Africa, 718
breast cancer, mortality, 943
Urine, genito-urinary cancer, diagnosis, minichromosome maintenance 5 protein in urine sediment, 1071
Urokinase-type plasminogen activator (uPA)
breast cancer, biomarkers, 116
inhibitor (PAI-1), breast cancer, biomarkers, 116
receptor (uPAR), 597
Urothelial cells, malignant transformation and CD40-mediated apoptosis, 1381 [cell lines]
UV radiation, skin cancer risk, 224

Vaccines
animal models, 808
clinical setting, 809
peptide-based, 805
single epitope versus polyepitope, 808
SV40 and cancer, 229 (correspondence)
T-cell responses, 812
Vanilloid capsaicin, tumor cells and, 1263 (editorial), 1281 [cell lines]
Vascular endothelial growth factor (VEGF)
metastasis, and intratumoral lymphatic vessels, 417 (commentary)
receptor 3 signaling, lymph node metastasis, 785 (editorial), 819 [cell line]
VHL tumor suppressor gene, renal cancer, 1569
Vinorelbine plus cisplatin, non-small-cell lung cancer, 291, 1172 (correspondence)
Viruses
Epstein-Barr virus, hematopoietic and lymphatic cancers, 678
Epstein-Barr virus, malignant and nonmalignant diseases, BZLF1 polymorphisms, 1733 (editorial), 1757
Epstein-Barr virus, nasopharyngeal cancer, 1594 (editorial), 1614
Epstein-Barr virus, nasopharyngeal cancer, HLA I and II alleles, Taiwan, 1780
HPV, SV40, EBV, and cancer, 1832 (commentary)
human papillomavirus, cervical cancer and, 1592 (editorial), 1604
HSV-2, cervical cancer and, 1592 (editorial), 1604
human herpesvirus 8, Kaposi's sarcoma, elderly males, 1333
JCV, medulloblastoma and, 240 (editorial), 267
Sindbis viral vectors, anticancer activity, 1790 [mice]
SV40, vaccines and cancer, 229 (correspondence)
against virus-induced tumors, 811
Vitamin D, breast cancer, and, 1301
Vitamin D_3-binding protein-derived macrophage activating factor, angiogenesis and, 1311 [cell lines]
Vocational adjustment, psychological therapies, 572, 1810 (correspondence)
Vomiting, psychological therapies, 572, 578, 1810 (correspondence)

Wilms tumor, insulin-like growth factor-II gene, subtypes, 1809 (correspondence)

X-ray screening, colorectal cancer, for persons at average risk, 1126, 1507 (*erratum*)

Zoledronic acid, prostate cancer, 1422 (editorial), 1458